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ABSTRACT  
Once thought to be a solved problem, the treatment of bacterial infections is currently a 
major human health concern. The increasing level of bacterial resistance to the existing 
antibiotics, together with the lack of any new effective antibacterial compounds in several 
decades, poses a great challenge to the development of new therapies. 
Antimicrobial peptides (AMPs) are one potential alternative to fight infectious diseases. 
These peptides are present in almost all living organisms, as part of their immune system, 
varying in length, sequence and structure. The mode of action of AMPs is still under 
debate, but in most cases this is thought to involve membrane disruption (by a variety of 
mechanisms) and in some cases they can also have internal targets. Beyond their 
capacity of directly killing bacteria and other microorganisms, the possibility of their use 
together with conventional antibiotics leading to a synergistic effect has also been 
described. 
In the present work the effect of AMPs from two families, cecropin A-melittin derivatives 
and lactoferrin-derived peptides, were tested for their effects on model membranes, and 
on two relevant pathogens: Leishmania and Mycobacterium avium. These are both 
intracellular pathogens of macrophages, which frequently act as opportunistic pathogens, 
in immunocompromised hosts. 
Lactoferrin-derived peptides were found to be leishmanicidal against L. donovani 
promastigotes and L. pifanoi amastigotes. In order to investigate the leishmanicidal 
mechanism of AMPs the permeabilization of Leishmania plasma membrane was 
evaluated by several assays allowing us to conclude that the mechanism of action of 
these peptides is based on the permeabilization of the plasma membrane. 
Cecropin A-melittin peptides directly inhibited the growth of M. avium in axenic cultures at 
high concentrations and they were toxic against macrophages. A Lactoferrin-derived 
peptide, lactoferricin, was active against M. avium in axenic cultures and when combined 
with ethambutol we observed a synergistic effect against M. avium growing inside 
macrophages. At odds, another peptide of the same family, LFChimera, significantly 
potentiated the growth of M. avium inside macrophages. 
In an attempt to contribute to the understanding of the mechanism of action of 
antimicrobial peptides, the interaction of AMPs with model membranes of 
phosphatidylethanolamine (PE), the major phospholipid in the bacterial cell membrane, 
was evaluated by Small Angle X-ray Diffraction (SAXD). Our results lead us to conclude 
that AMPs induce cubic phases in these model systems, which can be seen as a possible 
mechanism of their bactericidal action. 
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RESUMO 
O tratamento de infeções bacterianas constitui atualmente um dos maiores problemas de 
saúde humana. Os níveis crescentes de resistência de bactérias patogénicas aos 
antibióticos disponíveis, juntamente com a falta de novos fármacos eficazes em várias 
décadas, representam um grande desafio no desenvolvimento de novas terapias. 
Os péptidos antimicrobianos (PAMs) são uma potencial alternativa no combate às 
doenças infeciosas. Estes péptidos estão naturalmente presentes em quase todos os 
seres vivos, como parte do seu sistema imunológico, variando no tamanho, sequência e 
estrutura. Em geral, é aceite que o seu mecanismo de ação consiste em disrupção 
membranar por variados processos, podendo também atuar em alvos intracelulares. 
Além da sua capacidade para matar diretamente os microrganismos, os PAMs têm 
também a capacidade de atuar em conjunto com antibióticos resultando num efeito 
sinergistico. 
Neste trabalho foi avaliado o efeito de péptidos de duas famílias de PAMs, 
nomeadamente derivados da cecropina A-melitina e derivados da lactoferrina. O seu 
efeito foi testado em patogénios relevantes, Leishmania e Mycobacterium avium, ambos 
patogénios intracelulares de macrófagos, frequentemente responsáveis por infeções 
oportunistas em doentes imunocomprometidos, assim como em membranas modelo. 
Péptidos derivados da lactoferrina foram activos contra promastigotas de L. donovani e 
amastigotas de L. pifanoi. Para tentar esclarecer o mecanismo de ação destes péptidos, 
a permeabilização da membrana plasmática da Leishmania foi avaliada por diferentes 
técnicas permitindo-nos concluir que o mecanismo de acção destes péptidos contra 
Leishmania consiste na permeabilização da membrana plasmática. 
Péptidos derivados da cecropina A-melitina inibiram directamente o crescimento de M. 
avium mas apenas em concentrações muito altas, sendo também tóxicos para 
macrófagos. No caso dos péptidos derivados da lactoferrina, lactoferricina foi activa 
contra M. avium em culturas axénicas e quando em combinação com ethambutol existiu 
um efeito sinergistico contra M. avium a crescer dentro de macrófagos. LFChimera por 
outro lado potenciou o crescimento deste patogénio no interior dos macrófagos. 
Na tentativa de clarificar o mecanismo de ação destes péptidos, a interação de PAMs 
com membranas modelo de fosfatidiletanolamina (PE), o principal fosfolípido das 
membranas bacterianas, foi avaliada por difração de raios-X (Small Angle X-ray 
Diffraction – SAXD). Os nossos resultados mostram que os PAMs induzem a formação 
de fases cúbicas nestas membranas modelo, podendo a sua formação ser considerada 
como um possível mecanismo de ação bactericida. 
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THESIS ORGANIZATION 
This thesis is organized into four parts. 
 Part I comprises the introduction to the thesis theme, where the first section gives a 
global overview of the area and subsequent sections develop the more relevant topics. 
 Part II describes the objectives of this master thesis 
 Part III encompasses the experimental procedures and the results. This part is divided 
into three sections, corresponding to different projects performed during the course of 
the thesis. Each section includes its own Materials, Methods, and Results. 
 Part IV contains the overall Discussion and Conclusions of the work and Bibliography. 
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1. GENERAL INTRODUCTION  
The introduction of the first antibiotics in the clinical practice in the 1940s (Aminov, R.I. 
2009) started one of the greatest successes in the history of medicine. These 
pharmaceutical compounds saved millions of human lives throughout the last decades 
and made people believe that all bacterial infections could be treated and they would 
rapidly become a problem of the past. However this belief was proven to be wrong. After a 
few years antibiotic-resistant pathogens started to emerge and to disseminate. In 
response to that, new antibiotics had to be brought to the clinic and, during several 
decades, the number of deaths caused by infections continued to decline. Nowadays we 
face a re-emergence of infectious diseases and the appearance of multidrug-resistant 
“super-bugs”, the treatment of which is increasingly costly and prone to failure. Examples 
of these multidrug-resistant bacteria are: the methicillin-resistant Staphylococcus aureus 
(MRSA) that is responsible for a high percentage of hospital-acquired infections and that 
is spreading outside the hospital zones (Lohner, K. 2009), multidrug-resistant 
Mycobacterium tuberculosis with approximately 440 000 new cases emerging annually, 
causing at least 150 000 deaths (WHO 2011a), among many others. This alarming 
situation was originated from a combination of factors, such as, the excessive and 
inappropriate use of antibiotics in human and animal health (Lohner, K. & Blondelle, S.E. 
2005) and the almost complete absence of discovery of new antibiotics in recent years 
(only two new classes of antimicrobial compounds were introduced in the market in the 
last three decades) (Lohner, K. 2009). 
 
 
 
 
 
 
 
 
Figure 1 – Publicity poster from the World Health Organization (WHO) for the World Health Day 
2011, where the aim was to reach attention for the antimicrobial resistance problem (WHO 2011c). 
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Considering all this there is an urgent need to develop new and effective antimicrobial 
therapies. In this context antimicrobial peptides (AMPs) are one potential alternative to 
fight infectious diseases because their mode of action makes them less prone to 
resistance induction than currently used antibiotics and permits high activity against a vast 
range of microorganisms. AMPs are present in almost all living organisms, having broad 
functions in innate immunity, including immunomodulation, and providing a first line of 
defense against a wide variety of pathogens (Hancock, R.E. & Sahl, H.G. 2006; Lohner, K. 
2009). Their mechanism of action is not fully understood, but it is widely accepted that 
they act by disrupting the cellular membrane of pathogens, with the possibility of also 
acting on intracellular targets. Most of these peptides have multiple modes of action, and 
they work in a multiple-hit strategy which increases their efficiency and capacity to evade 
potential resistance mechanisms (Nguyen, L.T. et al. 2011). These characteristics may 
make AMPs useful in the clinic for a longer time, as compared to conventional antibiotics 
(which become obsolete, due to microbial resistance in 1 to 2 decades on average) 
(Hancock, R.E. & Sahl, H.G. 2006). 
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2. PATHOGENS 
In this work the antimicrobial activity of AMPs was assessed on different pathogens, 
namely Leishmania and Mycobacterium avium. In the next sections a brief introduction will 
be made to these microorganisms focusing on the epidemiology, structural characteristics, 
pathology, on the current treatments available and on the status of AMPs as potential 
agents to fight the diseases inflicted by these pathogens. 
2.1. LEISHMANIA 
Protozoan parasitic diseases, especially malaria, leishmaniasis, and trypanosomiasis, are 
considered neglected diseases and remain an unsolved public health problem in certain 
areas of the world, with extremely high death rates. The high mortality in developing 
countries is often due to the poor sanitary conditions and lack of efficient prophylactic 
measures, whereas in developed countries, some of these diseases that were eradicated 
are re-appearing especially as opportunistic diseases in immunocompromised hosts 
(Piscopo, T.V. & Mallia Azzopardi, C. 2007; Zucca, M. & Savoia, D. 2011).  
Leishmania is a genus of protozoan parasites that are transmitted to the mammalian host 
(e.g. canines, rodents and humans) by the bite of phlebotomine sand flies, and are the 
causative agents of a set of clinical diseases collectively known as leishmaniasis. The 
World Health Organization estimates that 350 million people are at risk of contracting 
leishmaniasis and approximately 2 million new cases occur per year. Visceral infections, 
caused by L. donovani and L. infantum, are highly fatal if not treated, and are responsible 
for 50 000 deaths annually, a rate surpassed among parasitic diseases only by malaria 
(WHO 2010). 
Leishmaniasis is endemic in more than 60 countries worldwide, mostly found in tropical 
and subtropical regions of the world. This disease is also endemic to all European 
Mediterranean countries including Portugal, mostly as canine leishmaniasis, in humans 
the opportunistic co-infection with HIV is of special relevance (WHO 2010). 
2.1.1. LEISHMANIASIS 
Clinical manifestations of leishmaniasis differ widely depending on the Leishmania 
species (there are at least 20 species) as well as on host factors such as immunity status 
(Goto, H. & Lindoso, J.L. 2010). The interplay between Leishmania and the mammalian 
host response is manifest not only in terms of clinical outcome but also in the rate of 
 18 
 
spontaneous healing and recurrent disease. Three main types of disease patterns occur: 
cutaneous, mucocutaneous and visceral infections (figure 2) (Piscopo, T.V. & Mallia 
Azzopardi, C. 2007; Zucca, M. & Savoia, D. 2011). 
 
   
 
 
 
 
 
Figure 2 – Clinical forms of leishmaniasis. A) Cutaneous, B) mucocutaneous and C) visceral 
leishmaniasis (WHO 2011b). 
Cutaneous leishmaniasis can potentially be associated with all Leishmania species, 
being the most common form of the disease characterized by the appearance of ulcers at 
the site of the bite on exposed parts of the body, such as the face, arms and legs. 
Normally these cutaneous forms of the disease are benign and the lesions spontaneously 
heal leaving scars. However there are some species of Leishmania that cause more 
complicated outcomes, for instance mucocutaneous leishmaniasis (WHO 2010). This 
form of the disease is caused by metastasis to the mucosal tissues of the mouth and 
upper respiratory tract by lymphatic and haematogenous dissemination potentially 
evolving to disfiguring lesions. Some Leishmania species that normally do not cause this 
type of leishmaniasis, have been reported to induce similar lesions in immunosuppressed 
patients (Goto, H. & Lindoso, J.L. 2010; WHO 2010). Visceral leishmaniasis is the most 
serious and complicated form of the disease and fatal if not treated. The infection is due to 
the invasion by the parasites of mononuclear phagocytic cells of the liver, spleen, bone 
marrow and intestinal mucosa. Aspects such as malnutrition, genetic factors and co-
infections that lead to immunosuppression are risk factors to develop the disease 
(Piscopo, T.V. & Mallia Azzopardi, C. 2007; WHO 2010). 
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2.1.2. LIFE CYCLE 
The protozoan parasite Leishmania has two major forms: the promastigote, the flagellated 
form that is transmitted to the vertebrate host by sand fly bites, and the intracellular 
amastigote, which lives inside mononuclear phagocytic cells of a wide variety of mammals 
(figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Life cycle of Leishmania. Schematic representation of the different stages of 
development of the parasite in the invertebrate host, sand fly, and in the vertebrate host, mammals 
(Adapted from: Banuls, A.L. et al. 2007; Sacks, D. & Noben-Trauth, N. 2002). 
In the invertebrate host the promastigote has an elongated shape and a long flagellum. 
This form infects the mammalian host when a parasitized female sand fly feeds from the 
blood of the vertebrate. The promastigotes that enter into the mammals organism are 
opsonized by serum components and then phagocytosed, primarily by macrophages and 
dendritic cells (Kima, P.E. 2007; Sacks, D. & Noben-Trauth, N. 2002). Inside the 
phagocytic cells, within the phagolysosome, the promastigotes undergo several structural 
and morphological changes to give rise to the intracellular amastigotes, which are ovoid 
and nonflagelated. Amastigotes proliferate within the phagolysosomes (or 
parasitophorous vacuoles) where they reproduce by binary fission until the number of 
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parasites increases enough for the cell to burst and free the amastigotes to infect other 
cells and continue their life cycles. The parasites could then go back to the invertebrate 
host when a sand fly ingests blood that contains mononuclear phagocytic cells infected 
with amastigotes (Banuls, A.L. et al. 2007; Kamhawi, S. 2006; Olivier, M. et al. 2005). 
One of the most remarkable accomplishments of Leishmania is that they successfully live 
inside mammalian cells that are responsible for killing pathogens, the macrophages. For 
that Leishmania had to evolve a range of sophisticated mechanisms to subvert host 
surveillance by altering the macrophage signal transduction machinery, thereby 
modulating the macrophage environment in its favor. Some examples of these 
mechanism are the production of lipophosphoglycan at the surface of the parasites that 
confers resistance to the lytic action of the complement system, allowing the infection of 
macrophages and creating appropriate conditions for the promastigote-to-amastigote 
differentiation (Lodge, R. & Descoteaux, A. 2005). Other examples include preventing the 
activation of macrophages defense mechanisms such as the production of oxygen and 
nitrogen reactive species and also inhibition of an adequate and protective T cell response 
by inhibiting the production of pro-inflammatory signals such as IL-12 and promoting the 
release of anti-inflammatory cytokines, like IL-10 and TGF-β. (Kima, P.E. 2007; Olivier, M. 
et al. 2005). 
2.1.3. TREATMENTS 
Drug treatment for leishmaniasis exists since the 20th Century, but only a limited range of 
drugs are available. The efficacy of these drugs is affected by a combination of factors, 
such as the differences in the sensitivity of Leishmania species to the drugs and their 
pharmacokinetic properties, and the immune status of the patient (Goto, H. & Lindoso, J.L. 
2010).  
The current treatment of leishmaniasis consists in the administration of pentavalent 
antimonials as a first option. As second line drugs there are some alternatives such as 
amphotericin B, which is effective in antimonials-resistant cases, miltefosine which was 
the first orally active drug made available against leishmaniasis, pentamidine that can also 
be used in the treatment of resistant cases of visceral leishmaniasis, as well as 
paromomycin (Goto, H. & Lindoso, J.L. 2010; Piscopo, T.V. & Mallia Azzopardi, C. 2007; 
WHO 2010). 
Parasite resistance to these conventional treatments, lack of efficacy, toxicity and high 
costs associated with them lead to a clear need to improve the existing drugs and to 
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identify new targets and in that way develop new therapies (Piscopo, T.V. & Mallia 
Azzopardi, C. 2007). However, the highest prevalence of parasitic diseases such as 
leishmaniasis occurs in the poorest areas of the world, and from the total investment in 
health research in the world, the work related with malaria, leishmaniasis and 
trypanosomiasis accounts for only about 0.1% whereas the contribution of these diseases 
to total burden is 5%. Nevertheless in the last years the search for new antiparasitic 
treatments has received new impulse thanks to new technical and political developments, 
and the appearance of new therapies, such as protease and topoisomerase inhibitors, 
RNA interference- based approaches, nano-drug delivery and proteomics, as well as 
antimicrobial peptides (Zucca, M. & Savoia, D. 2011). 
2.1.4. LEISHMANIA AS A TARGET OF AMPS 
In what concerns AMPs, protozoans have received much less attention as a target than 
pathogens such as bacteria or fungi, although a variety of in vivo and in vitro antiparasitic 
assays suggest that these compounds could represent a powerful tool for the 
development of new therapies as well as to complement current ones (Rivas, L. et al. 
2009). 
Following the discovery of AMPs, magainins and cecropins were the first antimicrobial 
peptides to display antiparasitic activities along with hybrids of cecropin A-melittin (Andreu, 
D. et al. 1992; Boman, H.G. et al. 1989; Mor, A. 2009). Histatin 5, a human salivary AMP, 
is also active against Leishmania, not by acting in the plasma membrane, as usual for 
AMPs, but by decreasing the mitochondrial ATP synthesis leading to cell death (Luque-
Ortega, J.R. et al. 2008). 
Although Leishmania are eukaryotic pathogens, their cytoplasmic membranes have higher 
levels of negative phospholipids, such as phosphatidylserine and phosphatidylinositol than 
higher eukaryotes, conferring them more susceptibility to the action of AMPs than 
mammal cells (Wassef, M.K. et al. 1985). Leishmania is an interesting model as a target 
for AMPs primarily due to the absence of barriers external to the plasma membrane 
contrary to what happens in bacteria. The promastigote form of the parasite is endowed 
with an anionic glycocalix, essentially composed of lipophosphoglycan (LPG), an anionic 
oligosaccharide, anchored to the membrane through glycosylinositolphospholipids (GIPLs) 
(figure 4). Abundant proteolytic activity also exists at the surface, due to the presence and 
activity of GPI-proteins and proteophosphoglycans (PPGs) (figure 4) (Rivas, L. et al. 
2009). These structures present at the surface of the membrane have some duality in 
what concerns resistance and/ or susceptibility to AMPs. The presence of a negatively 
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charged glycocalix can favor peptide interaction however they can also delay the 
interaction of the peptides with the cytoplasmic membrane diminishing their efficacy; the 
proteolytic activity at the surface of the membrane, can also confer resistance to AMPs 
due to increased possibility of peptide degradation. A second important characteristic of 
Leishmania cells is the fact that endo- and exocytosis are confined to a special area 
accounting for about 2% of the plasma membrane known as the flagellar pocket (deep 
invagination of the plasma membrane that is located at the base of the flagellum devoid of 
attached microtubules) (Morgan, G.W. et al. 2002; Overath, P. et al. 1997). Theoretically, 
this may somehow limit the repairing capacity of the membrane upon exposure to AMPs 
(Luque-Ortega, J.R. & Rivas, L. 2010). 
Although amastigotes can appear more vulnerable to AMPs due to the much less 
developed glycocalix (figure 4), their location inside phagocytic cells and the substantial 
changes in the membrane composition adopted by these parasites along their life cycle, 
can be barriers to the action of AMPs (Luque-Ortega, J.R. & Rivas, L. 2010). 
 
 
 
 
 
 
Figure 4 – Cytoplasmic membrane of Leishmania parasites. Comparison between the 
composition of the cellular membrane of promastigotes and amastigotes. LPG: lipophosphoglycan; 
PPGs: Proteophosphoglycans; GIPLs: glycosylinositolphospholipids (diagram kindly provided by 
Doctor Luís Rivas). 
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2.2. MYCOBACTERIUM  
Tuberculosis (TB) remains today one of the most deadly human diseases. WHO 
estimates that one-third of the world's population is currently infected with the TB bacillus 
with 5-10% of people developing the disease. In 2009 approximately 2 million people died 
of TB. The incidence of tuberculosis in the United States had been declining since the turn 
of the 20th century, however since 1985 it has been rising mainly due to the AIDS 
epidemic, the lack of efficacy of the anti-tuberculosis vaccine and the emergence of 
multidrug-resistant strains (Clemens, D.L. & Horwitz, M.A. 1995) The genus 
Mycobacterium includes not only Mycobacterium tuberculosis, the causative agent for TB 
discovered in 1882 by Robert Koch (Koul, A. et al. 2011), but other pathogenic species 
such as M. leprae and M. ulcerans, and non-pathogenic species, usually referred to as 
nontuberculous mycobacteria (NTM). More than 130 species of NTM are known and most 
of them are typically environmental organisms present in water, soil, dust and plants. 
Contact with these contaminated environments may be responsible for infection in 
humans and animals with the possibility of transmission from human to human being 
almost null (Pieters, J. 2001; Tortoli, E. 2006; Tortoli, E. 2009). The large majority of NTM 
are nonpathogenic for healthy individuals, but they can act as opportunists in 
immunocompromised patients, especially in AIDS patients. The consequences of 
mycobacterial infection depend on the virulence of the infecting Mycobacterium and the 
resistance of the host. In humans the outcome can range from relatively mild and transient 
symptoms, mostly caused by pulmonary infections, to a widely disseminated disease 
(Pieters, J. 2001; Tortoli, E. 2009). 
2.2.1. MYCOBACTERIA CELL WALL 
Mycobacteria cells are irregular rods, aerobic, and unable to form spores (Prescott, L.M. 
et al. 2002). Mycobacterium species are characterized by an extremely complex and 
highly impermeable cell wall, composed of mycolic acids, glycolipids, lipoglycans, 
polysaccharides and pore forming proteins (figure 5). This unique cell wall contributes to 
the capacity of the pathogen to survive inside the host and to resist the chemotherapy 
(Nigou, J. et al. 2003). 
The cell wall skeleton determines the size and shape of mycobacteria, and contains three 
different covalently linked layers, peptidoglycan, arabinogalactan and mycolic acids 
(Guenin-Mace, L. et al. 2009). The covalent linkage of the mycolic acids results in a 
hydrophobic layer of extremely low fluidity and high impermeability. Also bound to the 
mycolic acids by hydrophobic links, in the external side, are various free lipids such as 
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phenolic glycolipids, sulpholipids, among others. The outer layer of the cell wall that some 
authors refer to as capsule is mainly composed of polysaccharides such as glucan and 
arabinomannan (Abdallah, A.M. et al. 2007). 
The presence of mycolic acids and other lipids outside the peptidoglycan layer makes the 
mycobacteria acid-fast. This means these bacteria are not stained by the Gram stain, and 
have to be stained with a harsher treatment, the Ziehl-Neelsen method (Prescott, L.M. et 
al. 2002). 
 
 
 
 
 
 
 
 
Figure 5 – Mycobacterial cell wall. Schematic representation of one of the current views of the 
mycobacterial cell wall (Abdallah, A.M. et al. 2007). 
Mycobacterium plasma membrane, which is protected by the cell wall, is an asymmetric 
bilayer mostly composed of lipids and proteins, as any biological membranes. The 
phospholipid composition is very similar to all the other bacterial membranes being 
essentially composed of phosphatidylethanolamine, phosphatidylglicerol, 
diphosphatidylglicerol, and phosphatidylinositol mannosides, these last three conferring 
the membranes an overall negative charge. (Guenin-Mace, L. et al. 2009).  
2.2.2. MYCOBACTERIUM AVIUM 
Mycobacterium avium belongs to the Mycobacterium avium complex (MAC), along with M. 
intracellulare. Disseminated MAC was one of the first opportunistic infections detected on 
AIDS patients remaining until today a substantial cause of morbidity and mortality among 
these patients (Tortoli, E. 2009). HIV-infected patients with M. avium have serious 
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complications associated with debilitating symptoms and shortened survival. In 1994, in 
the United States, it was estimated that 37 000 people were infected with disseminated 
Mycobacterium avium complex, a greater number than the people infected by TB in this 
year also in the same country (Horsburgh, C.R. et al. 2001; Reed, C. et al. 2006). 
Infection of AIDS patients by M. avium occurs in advanced stages of the disease, when 
the levels of CD4+ T cells are very low. M. avium can also infect patients with other 
debilitating diseases, especially restrictive and obstructive pulmonary diseases, that 
compromise the immune system, such as chronic obstructive pulmonary disease, 
emphysema, chronic bronchitis and children with lymphadenitis (Appelberg, R. 2006b).  
M. avium, similar to other mycobacteria, is a facultative intracellular pathogen residing 
mainly inside macrophages (figure 6). The pathogenicity of the mycobacteria is directly 
related to their ability to persist in macrophages circumventing the host immune response. 
After being phagocytozed by macrophages the mycobacteria live inside the phagosomes 
of the host cells (Pieters, J. 2001). Normally the phagosome undergoes maturation that 
consist of a progressive acidification and several fusion and fission events, leading to 
fusion with lysosomes forming the phagolysosome that has an acidic environment and 
contains proteolytic enzymes that degrade the content of the vacuole (Gomes, M.S. et al. 
1999c). M. avium interferes with the intracellular trafficking of the macrophages, by 
inhibiting phagosome-lysosome fusion, escaping from harmful environments (e.g. acidic 
pH) and also by interacting with endosomes, allowing the bacteria to access nutrients that 
are required for their survival (Appelberg, R. 2006a; Appelberg, R. 2006b). 
 
 
 
 
 
Figure 6 – Mycobacterium avium. Spleen macrophages (from an AIDS patient) infected with M. 
avium complex (pink) stained with the Ziehl-Neelsen method (WebPath: The Internet Pathology 
Laboratory). 
The mechanism by which macrophages can inhibit the mycobacterial growth and the 
mechanisms used by mycobacteria to resist and live inside macrophages are partially 
understood. M. avium can grow exponentially inside non activated macrophages inhibiting 
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the production of superoxide, however this growth is more restrictive if the macrophages 
are activated with IFN-γ and TNF-α, independently of the production of nitrogen and 
oxygen reactive species (Gomes, M.S. & Appelberg, R. 2002; Gomes, M.S. et al. 1999b). 
Also mechanisms that lead to restriction of access to nutrients by mycobacteria and 
macrophage death pathways may contribute to the elimination of the pathogen 
(Appelberg, R. 2006a; Behar, S.M. et al. 2010). 
2.2.3. TREATMENTS 
Infections by mycobacteria are very difficult to treat due to a combination of factors, such 
as: i) the poor action of the antibiotics available, mainly due to the highly impermeable cell 
wall; ii) the fact that these are intracellular bacteria; iii) the long duration of the treatments, 
that much of the time the patients do not follow to the end and iv) the antibiotic resistance 
that is increasing worldwide. 
The basic treatment of all pathogenic mycobacteria consists of a combination of different 
antibiotics taken for several months. In the case of tuberculosis the treatment varies 
according to the susceptibility of the isolated strain to the available drugs, going from the 
administration of antibiotics such as isoniazid, rifampicin, pyrazinamide and ethambutol to 
fluoroquinolone or second-line injectable drugs, such as amikacin, kanamycin and 
capreomycin, that are all ineffective against extensively-drug resistant TB (Koul, A. et al. 
2011). 
In the case of Mycobacterium avium current therapy consists of ethambutol with a 
macrolide that can be azithromycin or clarithromycin, and rifamycin derivatives (rifampicin 
and rifabutin) taken for six months to one year with an overall clinical success rate of no 
more than 60% in AIDS patients (Deshpande, D. et al. 2010). The administration of an 
effective antiretroviral therapy in immunocompromised patients reduces the number of 
people at risk of developing disseminated MAC by restoring the immune function of the 
patients essentially by elevating the number of CD4+ T cells (Horsburgh, C.R. et al. 2001). 
The global control of mycobacterial infections will be achieved with new antimycobacterial 
drugs that follow some criteria: shorten treatment duration, target multidrug-resistant 
strains, a more simple treatment by reducing the daily pill burden and the dosing 
frequency, and the possibility of co-administration with anti-HIV drugs (Koul, A. et al. 
2011). 
Some alternative therapies consist in the combination of antibiotics with adjunctive 
immunomodulators – adjunctive immunotherapy – such as picolinic acid, that have shown 
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direct antimicrobial activity against both extracellular and intramacrophagic MAC 
organisms, alone and in combination with conventional antibiotics (Cai, S. et al. 2006). 
The observation that the growth of M. avium inside macrophages is directly proportional to 
the amount of iron available, and the fact that AIDS patients have increased iron 
deposition in different tissues favoring the growth of M. avium, makes the use of iron 
chelators, that deprives the mycobacteria from an essential nutrient for their survival, a 
promising road for the treatment of this disease. Recent studies have shown the efficacy 
of some iron chelators both in vitro and in animal models infected with M. avium 
(Fernandes, S.S. et al. 2010; Gomes, M.S. et al. 2001; Gomes, M.S. et al. 1999a). 
2.2.4. MYCOBACTERIA AS A TARGET OF AMPS 
Antimicrobial peptides, such as cathelicidins and defensins, like human neutrophil peptide 
(HNP) and human β-defensin 2 (HBD-2), have also shown activity against M. tuberculosis 
and M. avium (Jena, P. et al. 2011; Mendez-Samperio, P. 2008; Ogata, K. et al. 1992). 
The combination of HNPs with anti-tuberculosis drugs, like isoniazid and rifampicin, 
against intracellular mycobacteria resulted in a significant reduction in the mycobacterial 
load (Kalita, A. et al. 2004; Sharma, S. et al. 2000). This effect could be due to increased 
permeability of both mycobacterial cell wall and plasmatic membrane by AMPs increasing 
the access of the antibiotics to intracellular targets like DNA (Sharma, S. et al. 1999). By 
potentiating the effect of antibiotics, AMPs can allow the reduction of the therapeutic 
dosage of drugs to approximately half and also reduce the time of treatment (Kalita, A. et 
al. 2004). 
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3. ANTIMICROBIAL PEPTIDES (AMPS) 
Considering the potential of antimicrobial peptides as new alternative therapies to fight 
infectious diseases, in the next sections, several aspects concerning AMPs will be 
addressed, namely: their structural characteristics, mechanisms of action, role in the 
immunity, and the problems, successes and challenges of introducing AMPs in the clinical 
practice. 
The term “Antimicrobial peptide” refers to a large number of peptides first characterized on 
the basis of their activity against bacteria and fungi. They constitute a primitive immune 
defense mechanism and they were found, first in the 1980s, on a variety of eukaryotic 
organisms, from insects to humans (Nguyen, L.T. et al. 2011; Reddy, K.V. et al. 2004). 
Some of them were first isolated due to their antimicrobial activity, whereas others were 
discovered for various unrelated functions before their potential as antimicrobial peptides 
was recognized (Wiesner, J. & Vilcinskas, A. 2010). These peptides are multifunctional 
and act in concert with other immune mechanisms and have evolved in nature throughout 
centuries to protect their hosts against diverse pathogens, such as bacteria, fungi, virus, 
protozoa and even cancer cells (Nguyen, L.T. et al. 2011). So far, more than 1500 
peptides from different sources have been reported in The Antimicrobial Peptide 
Database – APD (http://aps.unmc.edu/AP/main.php) and the majority of them are 
classified as antibacterial peptides. Virtually all human tissues can produce AMPs, either 
constitutively or induced by inflammatory stimulus, more frequently in body sites exposed 
to pathogens, such as the skin or mucosa, or in some blood cell types, such as 
neutrophils, eosinophils and platelets (Wiesner, J. & Vilcinskas, A. 2010).  
Natural AMPs are gene-encoded and ribosome-synthesized peptides that derive from 
precursor peptides through one or more proteolytic activation steps. De novo design of 
synthetic peptides was introduced in the 1990s with the use of high-throughput 
combinatorial library screening, structure based modeling and predictive algorithms to 
determine the optimal active peptide. Although this approach produced interesting results, 
the need for a high initial investment in technology compared to traditional methods has 
delayed the widespread use of this approach. On the other hand, rational design of 
peptides using existent sequences as templates that are modified to obtain peptides with 
the desired properties (antimicrobial activity and selectivity) and the discovery of AMPs 
through the search within natural proteins (e.g. lactoferrin) have also led to the successful 
production of more potent antimicrobial peptides (Nguyen, L.T. et al. 2011). 
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3.1. STRUCTURAL CHARACTERISTICS 
Antimicrobial peptides vary widely in many aspects, such as length, sequence, structure 
and source, but there are some common traits for most of them, that are important for 
their antimicrobial activity. They can be defined as short (<50 amino-acids), with a positive 
net charge (generally +2 to +9, due to the existence of lysine and arginine residues) that 
allows them to interact with negatively charged membranes, such as bacterial membranes, 
although anionic antimicrobial peptides have also been described. They also have a 
substantial proportion of hydrophobic residues. AMPs have a random structure in solution 
but when in a membranous environment they adopt an amphipatic structure, allowing 
them to bind more efficiently to phospholipid membranes (Shai, Y. et al. 2006). The full 
classification of AMPs is difficult due to their huge diversity but almost all authors divide 
and classify the peptides based on their secondary structure. One of those classifications 
divides AMPs into three groups (table 1 and figure 7): α-helical peptides, β-sheet 
peptides and extended peptides which do not fold into regular secondary structures and 
are often composed of a high number of certain amino-acids, like histidine, tryptophan and 
arginine (Nguyen, L.T. et al. 2011). 
Table 1 – Overall characteristics of some AMPs (adapted from: Van 'T Hof, W. et al. 2001). 
Group Peptides Organism Source 
Antimicrobial 
activity 
a
 
Reference 
α-helical 
peptides 
melittin bee 
venom 
(apitoxin) 
G-; G+; V; H 
(Reddy, K.V. et al. 
2004) 
magainins frogs skin mucus G-; G+; F 
(Nguyen, L.T. et al. 
2011) 
cecropins 
insects: 
moth 
hemocytes G-; G+; F; P 
(Reddy, K.V. et al. 
2004) 
cathelicidins 
LL-37 
humans 
leukocytes, 
epithelia 
G-; G+ 
(Guaní-Guerra, E. et 
al. 2010; Nguyen, L.T. 
et al. 2011) 
Dermaseptins frogs skin mucus G-; G+; F 
(Van 'T Hof, W. et al. 
2001) 
β-sheet 
peptides 
lactoferricin 
cow, 
humans 
digested 
lactoferrin 
G-; G+; V; F; P; 
T 
(Chan, D.I. et al. 
2006) 
defensins humans 
leukocytes, 
epithelia 
G-; G+; V; F 
(Guaní-Guerra, E. et 
al. 2010) 
protegrins pig 
leukocytes, 
epithelia 
G-; G+; F 
(Reddy, K.V. et al. 
2004) 
extended 
peptides 
indolicin cow leukocytes G-; G+; V; F; P 
(Chan, D.I. et al. 
2006) 
tripticin pig leukocytes G-; G+; F 
(Chan, D.I. et al. 
2006) 
histatins humans saliva G-; G+; F 
(Van 'T Hof, W. et al. 
2001) 
PR-39 pig intestine G-; G+; 
(Chan, D.I. et al. 
2006) 
a
 G-: Gram-negative bacteria; G+: Gram-positive bacteria; F: fungi; P: protozoan; T: tumor; H: hemolytic. 
 31 
 
 
 
 
 
Figure 7 – The three major structures of AMPs. A) α-helical peptides B) β-sheet peptides C) 
extended peptides. Positively charged side chains are colored in blue, negatively charged side 
chains in red and remaining side chains in grey. PDB IDs: magainin 2: 2MAG; bovine lactoferricin: 
1LFC; indolicidin: 1G89 (adapted from: Nguyen, L.T. et al. 2011). 
3.2. MECHANISMS OF ACTION 
The mechanism of action of antimicrobial peptides is not yet fully understood but it is well 
known that the biophysical properties mentioned above (secondary structure, overall 
charge and hydrophobicity) play important roles in their interaction with pathogen 
membranes. Other parameters are important for their action, such as the membrane lipid 
composition, the peptide-to-lipid molar ratio, and environmental conditions like ionic 
strength and pH (Lohner, K. & Blondelle, S.E. 2005). Due to the high diversity of AMPs 
and their properties there is no universal mechanism for the action of all AMPs as they 
can act in multiple ways making difficult to unravel all the molecular events resulting from 
the interaction between peptides and membranes. The activity of AMPs is most probably 
not related to specific membrane protein receptors since studies using all D-amino acids 
instead of L-amino acids in magainin, cecropin and melittin, showed that these D-peptides 
exhibited similar activities than the natural ones, suggesting that the interaction between 
peptides and membranes does not depend on chiral centers (Merrifield, E.L. et al. 1995; 
Wade, D. et al. 1990). There are some proposed mechanisms, providing explanations of 
possible ways for the peptides to disrupt the membrane leading to cell death. Overall, all 
the proposed mechanisms rely on the same main factors for initial action: adsorption of 
AMPs onto the membrane due to electrostatic interactions between the cationic peptides 
and the headgroups of anionic phospholipids, and then they vary in the next steps of 
action. 
According to the barrel stave model (figure 8), peptides large enough (~ 22 amino acids) 
form transmembrane aqueous channels/pores by inserting into the hydrophobic core 
perpendicularly to the membrane plane where the hydrophobic region of the peptide is 
aligned with the acyl chains of the phospholipids while the peptide hydrophilic regions 
form the inner surface of the pore channel (figure 8). The continuous recruitment of 
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peptides to the membrane increases the pore size leading to leakage of the cells contents, 
membrane depolarization and thereby cell death (Nguyen, L.T. et al. 2011). The peptides 
arrangement in the membrane causes high repulsion due to their charges and this can 
culminate in the disintegration of the pore. This model is only possible for peptides with 
not too high charge and it is believed that the number of peptides acting by this 
mechanism is very low. An example is alamethicin from the fungus Trichoderma viridis, 
and perforin, produced by mammalian killer lymphocytes and complement component C9 
(Wiesner, J. & Vilcinskas, A. 2010). 
The carpet model (figure 8) proposes that the membrane surface is covered by the 
peptides, aligned parallel to the bilayer surface, in a “carpet like” manner, diminishing the 
fluidity of the membrane. When the concentration of the peptide reaches a threshold value 
the integrity of the membrane is lost leading to membrane micellization, toroidal pores or 
aggregated channels formation (see below) and cell death (figure 8) (Lohner, K. 2009).  
The formation of toroidal or wormhole pores (figure 8) is the best characterized and the 
most consistent mechanism of action of AMPs. This model can be seen as representing 
one of the possible final stages of the previous carpet model, where the formation of pores 
leads to disruption of the membranes. In fact, these two models have been unified in the 
so called “Shai-Matzusaki-Huang” model that proposes that peptides bind parallel to the 
membrane with the apolar amino acids penetrating partly into the hydrophobic core, while 
the cationic residues interact with the headgroups of anionic phospholipids, inducing 
membrane thinning and a curvature strain. To release this strain the orientation of the 
peptides changes from parallel to perpendicular, inducing bending of the membrane 
interface towards the hydrophobic interior, maintaining the contact between the peptides 
and the charged headgroups from the phospholipids. These events lead to the formation 
of toroidal pores composed by the peptides and the lipid headgroups (figure 8). Upon 
disintegration of the pores some peptides can be translocated to the inner leaflet of the 
membranes reaching the cytoplasm or the membrane can be disrupted due to 
depolarization or micellization, resulting in cell death (Nicolas, P. 2009; Rivas, L. et al. 
2009).  
Other mechanisms of action have recently been suggested that do not imply the 
recruitment of a high concentration of peptides to the membrane, and they do not 
necessarily exclude each other (or even the models explained above) (figure 8). Some 
examples are, lipid segregation, where the lipids can move laterally in the membrane 
and thus form domains rich in anionic lipids (induced by the presence of the positively 
charged peptide), and this can induce small leakage of intracellular contents and/ or 
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membrane destabilization and depolarization due to dissipation of the membrane 
potential; formation of non-bilayer intermediates in the membrane and non-lamellar 
structures; and membrane permeabilization and/ or depolarization due to an efflux of 
small anions across the bilayer by coupling with peptides. (Nguyen, L.T. et al. 2011). 
Whatever the mechanism is, peptide interaction with membranes can culminate in cell 
death by the dissipation of transmembrane electrochemical ion gradients, loss of 
metabolites, and eventually lysis of the cell (Wiesner, J. & Vilcinskas, A. 2010). If the 
peptides are translocated to the cytoplasm, with or without permeabilising the cytoplasmic 
membrane, some other effects could arise due to the existence of intracellular targets, 
such as DNA, RNA or protein synthesis and folding. Buforin is an example of a non-lytic 
peptide which although it has a high antimicrobial activity this does not correlate with lysis 
of the bacterial membrane. Instead the peptide translocates efficiently to the cytoplasm 
probably through the formation of short-lived toroidal pores, enabling this peptide to enter 
the cell and act on intracellular targets (Henriques, S.T. et al. 2006; Kobayashi, S. et al. 
2004; Kobayashi, S. et al. 2000). 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Proposed mechanisms of action for AMPs. Illustration of some of the proposed 
events/mechanisms occurring at the cytoplasmic membrane after a initial interaction of 
antimicrobial peptides with the membranes (Nguyen, L.T. et al. 2011). 
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AMPs can also be cytotoxic against cancerous cells promoting apoptosis (e.g. lactoferrin 
proved to inhibit the tumor growth and metastasis in a rodent model with breast cancer, 
while lactoferrricin causes apoptosis in Jurkat T-leukemia cells) (Iigo, M. et al. 2009; 
Mader, J.S. et al. 2007; Wiesner, J. & Vilcinskas, A. 2010). It is believed that this effect is 
first due to lysis of the cellular membrane of the cancerous cells, that are recognized by 
some AMPs due to the unusually high amounts of negatively charged gangliosides and 
phosphatidylserine (PS) in the surface of these cells, a negative membrane potential and 
a higher membrane fluidity, allowing the peptides to insert into the membrane more easily 
(Hoskin, D.W. & Ramamoorthy, A. 2008). Afterwards, mitochondrial membranes can also 
be disrupted due to entrance of the peptide into the cell, apoptosis pathways can be 
activated and angiogenesis inhibited (Gifford, J.L. et al. 2005; Guaní-Guerra, E. et al. 
2010). 
3.3. SELECTIVITY / TOXICITY 
Independently of how AMPs exert their activity against pathogens the peptides have to 
interact with the cellular membrane resulting either in disruption or traversing this barrier. 
This interaction must be as selective as possible regarding the distinction between 
mammalian cells (eukaryotic cells) and pathogen cells, such as bacteria (prokaryotic cells). 
Cytoplasmic membranes of mammalian cells are predominantly constituted by 
phospholipids and cholesterol. Phospholipids are asymmetrically distributed between the 
inner and the outer leaflet of the bilayer exposing predominantly zwitterionic 
phosphatidylcholine (PC) and sphingomyelin to the extracellular side. On the other hand, 
cytoplasmic bacterial membranes do not have cholesterol and are mainly composed of 
zwitterionic phosphotidylethanolamine (PE) and negatively charged phosphatidylglicerol 
(PG), diphosphatidylglicerol and cardiolipin, conferring an overall negative charge to the 
outer side of the cytoplasmatic membrane (Lohner, K. 2009; Lohner, K. & Blondelle, S.E. 
2005). The main principle of peptide interaction with membranes relies on electrostatic 
interactions between cationic peptides and negatively charged membranes and thus 
considering the composition of both cell types, bacteria are a preferential target for AMPs. 
However, before reaching the cytoplasmic membrane of the bacteria, peptides have to 
overcome other barriers. In the case of Gram-positive bacteria, a thick peptidoglycan layer 
embedded with teichoic and lipoteichoic acids (which are negatively charged) is present 
around the cell, exterior to the lipid membrane (figure 9). Gram-negative bacteria also 
have a complex cell wall consisting of an outer lipid membrane layer, with a unique and 
highly asymmetrical composition, and a layer of peptidoglycan (much thinner than that of 
Gram-positive bacteria) between the inner and the outer membranes (figure 9) (Cabeen, 
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M.T. & Jacobs-Wagner, C. 2005). In Gram-negatives outer membrane, 
lipopolysaccharides (LPS – negatively charged) are located exclusively in the outer leaflet 
and phospholipids are confined to the inner leaflet (figure 9) (Lohner, K. 2009; Lohner, K. 
& Blondelle, S.E. 2005). In the case of Mycobacteria, an even thicker and more complex 
cell wall is also present (see section 2.2.1). Even so, in normal conditions the overall 
charge of a bacterial cell wall is negative, increasing the chances of interaction with 
antimicrobial peptides. (Guenin-Mace, L. et al. 2009; Prescott, L.M. et al. 2002). 
 
 
 
 
 
 
 
 
 
Figure 9 – Bacteria cell wall. Schematic representation of the cell wall of a) Gram-positive and b) 
Gram-negative bacteria (Cabeen, M.T. & Jacobs-Wagner, C. 2005). 
The membrane potential can also contribute for the selectivity of AMPs since in 
eukaryotes it is less negative than in prokaryotes (Van 'T Hof, W. et al. 2001). 
Antimicrobial peptides can also kill eukaryotic pathogens, such as fungi and protozoa, 
raising the question of what are the features of the pathogens, either eukaryotes or 
prokaryotes that allows some AMPs to discriminate them from mammal cells. These 
specificity seems to rely on charge, since pathogens seems to have a higher percentage 
of anionic phospholipids than mammal cells, thus explaining the specificity of the cationic 
AMPs (Lohner, K. 2009; Lohner, K. & Blondelle, S.E. 2005). However some peptides do 
not distinguish host and pathogen cells being able to disrupt mammalian cells (e.g. 
melittin) and thus cannot be used in the clinic. The reasons behind this activity are not 
completely understood and are most probably due to the properties of the peptides, like a 
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high positive charge, too large hydrophobic surfaces, between others (Nguyen, L.T. et al. 
2011). In the evaluation of the activity of AMPs the cytotoxicity of these peptides towards 
mammalian cells should always be addressed. There are many different cytotoxicity 
assays that can be performed but the outcome of each of them strongly depends on many 
factors such as the origin and life storage of the mammal cells, the peptide-to-cell ratio, 
the medium used, between others, so the results must be carefully analyzed (Van 'T Hof, 
W. et al. 2001). Based on the results of cytotoxicity assays together with the antimicrobial 
activity of AMPs, the selectivity index, defined as the cytotoxicity activity divided by the 
antimicrobial activity, can be determined being a useful tool to predict the potential of a 
given AMP as a therapeutic agent. However, the characteristics of these peptides and the 
prediction of their action, either antimicrobial activity or cytotoxicity, is not straightforward 
and so they should be analyzed on a case-by-case basis. 
3.4. AMPS IN THE IMMUNITY 
Besides the role of AMPs as endogenous antibiotics (directly killing the pathogens), they 
can also participate in multiple aspects of immunity and for that they can also be called 
host defense peptides (HDPs). Combination of these different but complementary 
functions is essential for the effective control of infections in the host organism. AMPs 
seem to actively participate in the immune system either by immunomodulation, 
neutralization of endotoxins, enhancement of phagocytosis, induction of both 
angiogenesis and wound repair, leukocyte chemotaxis and synergism with cytokines 
(Yang, D. et al. 2002; Zaiou, M. 2007). Thus, in response to an infection, antimicrobial 
peptides can promote bacterial clearance not only through direct killing but also through 
the establishment of immune cell circuits (Auvynet, C. & Rosenstein, Y. 2009; Guaní-
Guerra, E. et al. 2010). 
As a consequence of the actions stated above these peptides are also involved in 
autoimmunity. The abnormal concentration, processing or signaling of AMPs is associated 
with a growing list of autoimmune diseases (figure 10), in which these peptides usually act, 
not as a single direct cause but as an important factor that influences the outcome of the 
diseases (Guaní-Guerra, E. et al. 2010). 
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Figure 10 – Role of AMPs in the immune system. Exemplification of some of the immune 
processes and inflammatory diseases where AMPs are involved (Guaní-Guerra, E. et al. 2010). 
3.5. RESISTANCE TO AMPS 
Induction of resistance is less likely for AMPs when compared to conventional antibiotics, 
due to the fast kinetics of the antimicrobial process and to the nature of the target – 
plasma membrane – since it would require an overall reorganization of the cell membrane 
structure, namely the phospholipid composition, affecting simultaneously the pleiade of 
transport systems and the enzymes embedded in the phospholipid matrix. Although in 
principle acquiring resistance to AMPs is more difficult, it has been pointed that it might 
have more severe effects if it led to cross-resistance to innate human antimicrobial 
peptides (Hancock, R.E. & Sahl, H.G. 2006). 
The most common mechanisms of bacterial resistance to AMPs described so far consist 
in the modification of the bacterial envelope leading to charge reduction and the 
proteolytic cleavage of peptides (Wiesner, J. & Vilcinskas, A. 2010). These mechanisms 
include the production of secreted proteins or cell-surface proteins that irreversibly binds 
or cleaves AMPs and glycopolymeric matrices that trap the peptides preventing their 
access to the bacterial cytoplasmic membrane (figure 11). Electrostatic repulsion of AMPs 
can also arise from several modifications such as substitutions of lipid A of LPS by 
aminoarabinose and ethanolamine, modification of phosphatidylglicerol by ligation of a L-
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lysine, or esterification of theicoic acids (WTA and LTA) by D-alanine, culminating in the 
reduction of the bacterial negative surface charge. In addition, increased resistance is 
achieved by changing membrane fluidity by modification of fatty acid acylation pattern of 
lipid A of LPS (figure 11) (Koprivnjak, T. & Peschel, A. 2011). 
For these mechanisms and modifications to take place, bacteria have to sense and 
respond to the presence of AMPs by up regulating the genes responsible for their 
resistance mechanism. Discovery of these mechanisms could point towards new and 
attractive targets for the development of antimicrobial drugs. 
 
 
 
 
 
 
 
Figure 11 – Sensing and responding to AMPs in Gram-negative and Gram-positive bacteria. 
Exemplification of some of the bacterial resistance mechanism to AMPs. WTA and LTA – theicoic 
acids; LPS – lipopolysaccharide (adapted from: Koprivnjak, T. & Peschel, A. 2011). 
3.6. AMPS IN THE CLINIC: SUCCESS, PROBLEMS AND CHALLENGES 
In the last years, since the discovery of the potential of antimicrobial peptides as new 
therapies to fight infectious diseases, there has been a tremendous effort to try to get 
these peptides into clinical trials and eventually use them in the clinic. Cationic peptides 
such as polymyxin B and gramicidin S have been used for a long time in the clinic as 
topical agents, and the lantibiotic nisin, produced by fermentation using Lactococcus lactis 
is used as an antimicrobial food addictive (Hancock, R.E. & Sahl, H.G. 2006).  
Several new generation antimicrobial peptides are in different stages of clinical trials but 
only a few are in the late stages phase III (table 2) (Godballe, T. et al. 2011). As drug 
candidates AMPs present some disadvantages due to their peptidic nature, including 
reduced activity in presence of salts and divalent cations, susceptibility to pH changes and 
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to protease and other plasma components’ activity, resulting in low metabolic stability and 
bioavailability, and reduced in vivo half-lives (Rotem, S. & Mor, A. 2009). The root of 
administration is also a problem since they would not be reabsorbed from the intestinal 
tract if administered orally, and if injected they could trigger immune responses that 
neutralize the active component or induce allergic reactions. So they should be 
administered as topical drugs for the treatment of skin and wound infections, limiting their 
applicability (Wiesner, J. & Vilcinskas, A. 2010). Other safety considerations should be 
taken into account. They can cross-react with receptors for neuropeptides and peptide 
hormones, and the rapidly degradation of AMPs could lead to unwanted levels of amino 
acids for which some patients are sensitive, like glutamate (Chinese restaurant syndrome) 
and phenylalanine (phenylketonuria) (Van 'T Hof, W. et al. 2001).  
The high cost of production associated with peptide synthesis is another drawback in the 
clinical application of these peptides. If the peptides have to be applied as topical 
formulations, the amount of peptide applied needs to be much higher and therefore the 
costs will be higher as well. Even when AMPs successfully finished several phase III trials, 
in most of the cases, they were not able to demonstrate superior protection when 
compared to traditional therapies (Godballe, T. et al. 2011). 
Several approaches have been adopted to try to overcome these problems, keeping in 
mind that the requirements for antimicrobial activity do not rely on a defined secondary 
structure or even in a consensus sequence, which was not identified when several 
sequences of natural AMPs deposited in the Antimicrobial Sequence Database – AMSDb 
(http://www.bbcm.univ.trieste.it/~tossi/amsdb.html) were analyzed (Rotem, S. & Mor, A. 
2009). The only common trait to all of them, as mentioned above (3.1) is the occurrence of 
both hydrophobic and positively charged amino acids. In this context some solutions have 
been proposed: i) the use of D-amino acids (rather than L-amino acids) which are 
resistant to proteases but have higher costs when compared with L-amino acids; ii) the 
use of nonpeptidic backbones (peptidomimetics); iii) formulation to improve stability, for 
example in liposomes; iv) pro-drug molecules, among others (Hancock, R.E. & Sahl, H.G. 
2006). 
Peptidomimetics (mimics of AMPs) deserves a special word, since this approach 
conserves the important features mentioned before (hydrophobicity and charge), and the 
antimicrobial activity, trying to solve some of the problems associated with natural 
peptides (costs, susceptibility to proteases, etc.) (Godballe, T. et al. 2011). 
Peptidomimetics refers to any oligomeric sequence designed to mimic a peptide structure 
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and/ or function but whose backbone is not solely based on α-amino acids (Rotem, S. & 
Mor, A. 2009). 
Table 2 – Antimicrobial peptides and mimetics in clinical development (adapted from: Godballe, T. 
et al. 2011; Guaní-Guerra, E. et al. 2010; Hancock, R.E. & Sahl, H.G. 2006; Wiesner, J. & 
Vilcinskas, A. 2010). 
Peptide 
Peptide 
class 
Clinical Use Outcome 
hLF 1-11 Lactoferrin Bacterial hospital infections 
Safety in humans 
established 
P-113 Histatins 
Used as mouth rinse for treatment 
of plaques and gingivitis 
Improvement in certain dose 
groups and certain 
populations 
Pexiganan Magainins Diabetic foot ulcers 
Comparably effective to 
ofloxacin 
Iseganan Protegrins 
Stomatitis associated with 
chemotherapy; oral mucositis 
associated with radiotherapy;  
ventilator-associated pneumonia 
No efficacy 
Omiganan Indolicin 
Central catheter-related 
bloodstream infections 
Significantly superior to 
povidone iodine in reduction 
of catheter colonisation and 
catheter-related local site 
infections 
Lytixar
TM 
(LTX-109) 
Defensin 
mimetic 
Nasal decolonisation of methicillin-
resistant S. aureus (MRSA); 
Skin infections caused by Gram-
positive bacteria 
Bactericidal and effective 
against wild-type as well as 
drug-resistant bacteria such 
as MRSA 
CeraShield
TM
 
Ceragenins 
mimetic 
Multi-drug resistant strains 
Positive results in preclinical 
studies 
 
3.7. CECROPIN A-MELITTIN-DERIVED PEPTIDES 
Cecropin A, with 37 amino acids, was the first antimicrobial peptide from an insect to be 
reported, and it is active on Gram-negative and Gram-positive bacteria and forms a nearly 
perfect amphipatic α-helix (Andreu, D. et al. 1992; Boman, H.G. et al. 1989). This peptide 
interacts with lipid membranes forming voltage-dependent channels that collapse the ionic 
gradients (Diaz-Achirica, P. et al. 1994). 
Melittin, from the bee venom toxin, has a variety of toxic properties namely a high 
hemolytic activity. This peptide adopts an α-helical conformation aggregating into 
tetramers and is used as a model peptide to monitor lipid–protein interactions using a 
variety of biophysical techniques (Raghuraman, H. & Chattopadhyay, A. 2007). 
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These two peptides, cecropin A and melittin, are composed by hydrophilic and 
hydrophobic domains separated by a flexible hinge region, and therefore they adopt an α-
helix – hinge – α-helix conformation, the only difference is the reverse polarity. The 
hydrophobic region of cecropin A is localized on the C-terminal whereas in melittin is 
localized on the N-terminal (Boman, H.G. et al. 1989). In an attempt to obtain antimicrobial 
peptides with strong bactericidal activity and lower hemolytic properties, H.G. Boman, et al 
in 1989 synthesized for the first time cecropin A-melittin hybrids, and they found that 
these hybrids had better antimicrobial properties than the parental compounds (Boman, 
H.G. et al. 1989). In particular a hybrid formed by the first 8 amino acids of the cationic 
region of cecropin A and the first 18 amino acids from the hydrophobic and nonhemolytic 
region of mellitin (CA(1-8)M(1-18)) exhibited a wider spectrum of activity and improved 
potency relative to cecropin A without the cytotoxic effects of melittin (Boman, H.G. et al. 
1989). In the continuation of this work, D. Andreu et al in 1992 synthesized shorter hybrids 
(15 aa) that retained a significant activity when compared to the larger versions of the 
hybrid, especially CA(1-7)M(2-9) (Andreu, D. et al. 1992). 
The mechanism of action of these hybrids is thought to be membrane disruption due to 
the formation of ionic channels (larger hybrids) or disintegration of the membrane due to a 
detergent-like action (shorter hybrids) or even the formation of toroidal pores (Abrunhosa, 
F. et al. 2005; Andreu, D. et al. 1992; Bastos, M. et al. 2008; Diaz-Achirica, P. et al. 1994). 
D-enantiomers of all the hybrids were synthesized and tested whether they required 
interaction with receptors to exert their antimicrobial activity. The antimicrobial activity of 
the D-enantiomers was quantitatively equivalent to that of the L-enantiomers. This is 
interpreted to mean that the peptides do not act by tight interactions with chiral receptors, 
enzymes or lipids in the lysis and killing of the pathogens (Merrifield, E.L. et al. 1995; 
Wade, D. et al. 1990). 
Although the aim of the synthesis of these hybrids was the reduction of hemolytic activity 
together with a potent antimicrobial activity, the first goal was not successfully achieved. 
The hybrids CA(1-8)M(1-18) and CA(1-7)M(2-9), especially the last one, are able to 
interact and disrupt zwitterionic model membranes (composed by phosphatidylcholine - 
PC), a model for erythrocytes, and toxicity towards erythrocytes was also described for 
them (Abrunhosa, F. et al. 2005; Fernandez-Reyes, M. et al. 2010). In an attempt to 
preserve the high antimicrobial activity of CA(1-7)M(2-9) but decreasing the hemolytic 
activity, some additional modifications where performed in this hybrid peptide.  
Peptide optimization by residue-specific modifications is one of the most effective and 
used strategies to obtain more active peptides with lower hemolytic activity. There are 
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some modifications that play important roles in vivo, like methylation, acetylation, 
ubiquitination, sumoylation or citrullination (Fernandez-Reyes, M. et al. 2010). Previous 
studies showed that upon methylation of all the amino groups of melittin (all the hydrogen 
atoms of the amino groups are replaced by methyl groups) the peptide entirely lost its 
hemolytic activity (Ramalingam, K. & Bello, J. 1992). The decrease of the hemolytic 
activity is probably due to the loss of hydrogen bonding ability of the amino groups and for 
the introduction of some steric effects as a result of the bulky of trimethylammonium 
groups. However this peptide still retains the same global positive charge so the 
antimicrobial activity should not be comprised (Ramalingam, K. & Bello, J. 1992). In fact, 
recently, a systematic study to assay the effect of lysine Nε-trimethylation (figure 12) on 
the hemolytic and the antimicrobial activity of a cecropin A-mellitin hybrid, CA(1-7)M(2-9), 
shows that all trimethylated peptides have a significantly lower hemolytic activity when 
compared to the parental hybrid peptide, where more resistant to proteolysis, and some of 
them retain a high antimicrobial activity both against Leishmania parasites and Gram-
positive (Staphylococcus aureus) and Gram-negative (Acinetobacter baumannii) bacteria 
(Fernandez-Reyes, M. et al. 2010). In this study the single trimethylated peptides on a 
lysine at position 6 (K6) and 7 (K7) (figure 13) revealed to have the better selectivity index 
(defined as the ratio between the hemolytic activity and the antimicrobial activity) of all the 
peptides and antimicrobial activities in the range of micromolar (Fernandez-Reyes, M. et 
al. 2010). In a biophysical approach K6 and K7 retain the ability to interact with partially 
negatively charged model membranes (mainly by segregation mechanisms) whereas they 
do not interact significantly with zwitterionic model membranes of PC (model membranes 
for erythrocytes) at odds with the parental hybrid peptide that disturbs all these model 
membranes (Teixeira, V. et al. 2010). The combination of these findings has highlighted 
the potentiality of lysine trimethylation as a powerful tool to overcome some of the 
problems for the applicability of AMPs as pharmacological agents, such as toxicity and 
susceptibility to proteases. 
 
 
 
 
 
Figure 12 – Lysine N
ε
-trimethylation. Trimethylation of the amino group on the ε-carbon of a 
lysine. 
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Figure 13 – Cecropin A-melittin hybris. A) Secondary structure of CA(1-7)M(2-9) (the 
corresponding part of cecropin A in purple and melittin in lilac). B) Positions of the trimethyl groups 
on K6 and K7 peptides (adapted from: Teixeira, V. et al. 2010). 
3.8. LACTOFERRIN-DERIVED PEPTIDES 
Lactoferrin (LF) is a mammalian iron-binding glycoprotein of 80 kDa, that belongs to the 
transferrin family (Pierce, A. & Legrand, D. 2009). Contrarily to transferrin, that appears 
primarily in the bloodstream delivering iron to the cells, lactoferrin is mostly found in 
exocrine secretions, like milk, tear fluid and seminal plasma, and in neutrophil granules 
playing an important role in maternal and innate immunity (Wiesner, J. & Vilcinskas, A. 
2010). This is a multifunctional protein that has antibacterial, antiviral, antifungal and 
antiparasitic activities and is also implicated in protection against cancer development and 
metastasis owing to its immunomodulatory potential (Pierce, A. & Legrand, D. 2009; 
Wiesner, J. & Vilcinskas, A. 2010). In the beginning, it was thought that the antibacterial 
activity of lactoferrin was only due to its ability to sequester iron, an essential nutrient, 
from bacteria (Jenssen, H. & Hancock, R.E. 2009). Now it is known that allied to that, the 
existence of particular domains, such as the highly cationic N1 terminal domain, where 
two antimicrobial peptides are found namely, lactoferricin and lactoferrampin, are crucial 
for the antimicrobial activities of lactoferrin (figure 14). 
 
 
 
 
 
Figure 14 – Bovine lactoferrin. Structural model representing the polypeptide backbone of bovine 
lactoferrin (PDB ID: 1BLF). The positions of the two bond Fe
3+
 ions, lactoferricin and lactoferrampin, 
these last two in the N1 domain, are indicated (adapted from: Wiesner, J. & Vilcinskas, A. 2010). 
A                B 
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Lactoferricin is obtained by pepsin digestion of lactoferrin, and has been extensively 
studied. The bovine peptide is constituted by 25 amino acids, corresponding to the amino 
acids 17-41 in the native protein (bovine lactoferrin) it has a disulfide bond between two 
cysteine residues, and forms a β-sheet structure (Chan, D.I. et al. 2006; Gifford, J.L. et al. 
2005). Antimicrobial activity of lactoferricin ranges from several Gram-negative to Gram-
positive bacteria, (Jenssen, H. & Hancock, R.E. 2009; Oo, T.Z. et al. 2010; Sanchez-
Gomez, S. et al. 2011) fungi, protozoan and virus. Lactoferricin has been shown to have 
antitumor effects, like inhibition of tumor metastasis, suppression of tumor-induced 
angiogenesis and significant reduction of solid tumor (fibrosarcomas, melanomas, 
coloncarcinomas) size in mice, without affecting erythrocytes or fibroblasts (Eliassen, L.T. 
et al. 2002; Gifford, J.L. et al. 2005; Yoo, Y.C. et al. 1997a; Yoo, Y.C. et al. 1997b). This 
peptide can also have immunomodulatory properties, playing a role in the innate and 
adaptive immune system, and it was also proposed that it inhibits septic shock by binding 
to endotoxins (Chan, D.I. et al. 2006; Yamauchi, K. et al. 1993). J. Groenink, et al in 1999 
synthesized shorter peptides with sequences homologous to the N-terminal domain of 
bovine and human lactoferricin, and found that of the peptides tested, bovine lactoferricin 
containing amino acids 17-30 (LFcin17-30) had the higher number of positively charged 
residues and the highest antimicrobial activity against both Gram-positive and Gram-
negative bacteria (Groenink, J. et al. 1999). The corresponding human peptide, hLFcin 
with the first 11 amino acids from human lactoferrin (hLFcin1-11) was demonstrated to be 
active against a variety of bacteria, such as Acinetobacter baumanii and Stahphylococcus 
aureus and fungi, especially Candida albicans. A clinical phase I trial using this peptide to 
combat bacterial hospital infections has been completed, and the overall safety was 
proved in preclinical and clinical studies (table 2) (Wiesner, J. & Vilcinskas, A. 2010) 
(www.am-pharma.com). 
Recently, another peptide in the N1 domain of bovine lactoferrin was identified by the 
group of Jan G. Bolscher, namely lactoferrampin containing the amino acids 268-284 
(LFampin268-284). This peptide exhibited antimicrobial activity against a broad range of 
pathogens, different from the activity of lactoferricin, especially against Candida albicans 
and several bacteria, (Van Der Kraan, M.I. et al. 2004). Systematic studies, using the 
initial sequence of lactoferrampin to obtain other peptides by truncation and/ or extension, 
have shown that lactoferrampin 265-284 (LFampin265-284) was the shortest and most 
active peptide, especially against C. albicans (Van Der Kraan, M.I. et al. 2005a; Van Der 
Kraan, M.I. et al. 2005b). The three extra amino acids (Aspartic acid-Leucine-Isoleucine) 
did not confer any additional positive charge (one of the most important characteristics for 
AMPs) since the first is negatively charged and the other two are uncharged. Instead, this 
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N-terminal sequence endowed lactoferrampin with a high tendency to adopt a more stable 
amphipatic α-helix, enhancing in this way its microbicidal activity (Haney, E.F. et al. 2009; 
Van Der Kraan, M.I. et al. 2005a; Van Der Kraan, M.I. et al. 2006). 
Lactoferricin and lactoferrampin are spatially close in lactoferrin, making it plausible that 
they can cooperate in many of the beneficial properties of this protein. To test if these 
peptides would form a functional unit, a chimeric peptide (LFChimera) containing 
LFcin17-30 and LFampin265-284 was synthesized by Jan G. Bolscher (Bolscher, J.G.M. 
et al. 2009). To try to mimic the spatial topology of these two peptides in lactoferrin, 
LFcin17-30 and LFampin265-284 are coupled by their C-terminals to the α- and ε-amino 
groups, respectively, of an additional lysine leaving the two N-terminals as free ends 
(figure 15). LFChimera displays a strong activity against a wide variety of pathogens such 
as Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Vibrio 
parahaemolyticus, Entamoeba histolytica, which is maintained in different physiological 
conditions (including high ionic strength and rich growth medium) (Bolscher, J.G.M. et al. 
2009; Flores-Villasenor, H. et al. 2010; Leon-Sicairos, N. et al. 2009; Lopez-Soto, F. et al. 
2010). 
 
 
 
 
Figure 15 – Lactoferrin-derived peptides. A) Ribbon diagram of bovine lactoferrin with LFcin17-
30 (yellow) and LFampin265-284 (red). B) Designed of LFChimera composed by LFcin17-30 and 
LFampin265-284 coupled by an additional lysine (K) (adapted from: Bolscher, J.G.M. et al. 2009). 
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4. LIPIDS IN BIOLOGICAL AND MODEL MEMBRANES 
Biological membranes are mainly composed by a lipid matrix that surrounds all other 
components, like proteins, glycoproteins and glycolipids that performs crucial functions to 
the life of the cell. Phospholipids, the building blocks of the cellular compartments, are 
amphiphilic molecules composed by a hydrophilic headgroup and a hydrophobic tail that 
consist in the hydrocarbon chains. The lipid composition is different between organisms, 
and even cell types of the same organism. The phospholipid distribution between the 
inner and outer leaflets of the lipid bilayer is asymmetrical, and some lipids are richer in 
one leaflet than the other (Pozo Navas, B. et al. 2005).  
Although, in the past, the widespread opinion was that lipids are passive components in 
biological membranes and that only proteins have specific physiological functions, it is 
now known that lipid molecules are dynamic and actively involved in various biological 
processes being not only a scaffold for proteins (Haney, E.F. et al. 2010; Luzzati, V. 1997). 
4.1. LIPID POLYMORPHISM 
The way that lipids are structurally organized when in contact with water, is highly variable, 
depending on their intrinsic properties, on the composition of the medium (pH, ionic 
strength, additives, etc), as well as on temperature and water content, giving rise to a 
complex phase-diagram (figure 16).  
 
 
 
 
 
 
 
 
Figure 16 – Temperature-composition phase diagram of monoolein. The phases formed by 
the lipid monoolein depend on temperature and hydration as illustrated in this phase diagram 
(adapted from: Qiu, H. & Caffrey, M. 2000). 
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This high polymorphism allows them to self-assemble into different phases and three-
dimensional ordered structures, that are usually classified as lamellar, and non-lamellar 
(such as hexagonal and cubic) phases. These non-lamellar phases were first 
characterized by Luzzati and coworkers using X-ray scattering techniques to analyze the 
three-dimensional arrangement of numerous membranes (Haney, E.F. et al. 2010).  
Different lipids have different propensity to form the different lipid phases mainly due to 
the relative size of their polar headgroup and apolar tails, that are responsible for 
determining the size and shape of the lipid molecule (figure 17) (Tresset, G. 2009). In 
cases where the headgroup and the hydrocarbon chains have similar cross-sectional 
areas, the molecule has a cylindrical shape (e.g. phosphatidylcholine - PC and 
phosphatidylserine). Lipids with a small headgroup like phosphatidylethanolamine (PE) 
have the structure of a truncated cone. In contrast when the hydrophobic part occupies a 
relatively smaller surface area, the molecule has the shape of an inverted cone (e.g. 
lysophosphatidylcholine) (figure 17) (Sprong, H. et al. 2001). 
 
 
 
Figure 17 – Phospholipids molecular shapes: inverted cone (LPC - lysophosphatidylcholine), 
cylindrical (PC - phosphatidylcholine) and truncated cone (PE - phosphatidylethanolamine), and 
their role in the shape of the cellular membrane (adapted from: Sprong, H. et al. 2001). 
The functional structure of a biological membrane is a lamellar lipid phase that acts as a 
fundamental permeability barrier. Lamellar phases are characterized by two opposing lipid 
monolayers with the hydrocarbon chains facing each other. Two types of lamellar phases 
can occur, a liquid crystalline or fluid lamellar phase (Lα) that occurs at higher 
temperatures, where the hydrocarbon chains are in a melted and fluid state allowing the 
membrane to spontaneously reorganize upon external stimulus, and a gel lamellar phase 
(Lβ) (lower temperatures) in which the hydrocarbon chains are extended and rigid (figure 
18) (Haney, E.F. et al. 2010). The typical state in biological membranes is the liquid 
crystalline or fluid lamellar state. Lamellar phases typically occur for lipids with a packing 
parameter (p) close to 1, which means that an individual molecule fits to a cylinder (e.g. 
PC) (figure 17) (Tresset, G. 2009).  
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Figure 18 – Lamellar phases. Schematic representation of the structure and orientation of the 
phospholipids hydrocarbon chains in the two lamellar phases, gel (Lβ) and fluid (Lα) (adapted from: 
Tresset, G. 2009). 
Although the maintenance of a stable bilayer is essential for normal membrane function, it 
is well known that in some cases, membranes containing high amounts of non-lamellar 
phase-forming lipids (e.g. phosphatidylethanolamine) have the ability to form more 
complex 3D morphologies, non-lamellar structures such as hexagonal and cubic phases, 
that are believed to play important roles in biological processes (Lohner, K. 2009; Lohner, 
K. & Blondelle, S.E. 2005). 
Hexagonal phases are made of lipids that all together adopt a cylindrical shape. When the 
phospholipids headgroups are oriented towards the core of the cylinder, that is filled with 
water, the structure is called inverted hexagonal phase – HII, whereas in a normal/ micellar 
hexagonal phase – HI, the centers of the cylinders consist of the hydrocarbon chains or 
phospholipid tails (figure 19). The HII is the simplest non-lamellar structure implied in 
membrane fusion processes. Very few lipids adopt an HI phase (Haney, E.F. et al. 2010; 
Tresset, G. 2009). 
The transition from lamellar to hexagonal phase occurs with increasing temperature as the 
interfacial area expands leading to unfavorable contact between aqueous and 
hydrophobic regions resulting in the formation of inverted hexagonal phases (Rappolt, M. 
et al. 2003). 
 
 
 
 
Figure 19 – Hexagonal phases. Adopted orientation of phospholipids in the different hexagonal 
phases HI and HII. In red the headgroups of phospholipids (hydrophilic region) and in grey the 
hydrocarbon chains (hydrophobic region) (Tresset, G. 2009).  
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Other important non-lamellar structures are the three-dimensional cubic phases. The 
cubic symmetry is attributed not only to a lipid phase but to a large family of phases that 
are complex and diverse (Luzzati, V. et al. 1997). Several cubic phases are known and 
they can be divided essentially into two classes, bicontinuous and micellar phases. The 
bicontinuous phases are unique and consist on a single bilayer folded into three-
dimensional cubic network separating two disjointed water compartments with continuous 
regions of both polar (hydrophilic headgroups) and non-polar (hydrocarbon chains) 
structures (Ia3d, Pn3m, Im3m) whereas the micellar phases are impervious to water-
soluble components and the structure is made of disjointed micelles with different sizes 
allowing a more efficient packing on a cubic lattice (e.g. Fd3m, Pm3n) (figure 20) (Luzzati, 
V. 1997; Tresset, G. 2009). 
 
 
 
 
 
 
 
 
 
Figure 20 – Cubic phases of lipids. Bicontinuous cubic phases: Im3m, Pn3m and Ia3d; and a 
micellar cubic phase (Fd3m) (adapted from: Tresset, G. 2009). 
Growing evidences show that cubic phases are ubiquitous in the biological world as they 
have been detected in the plasma membrane of archaebacteria, as well as in the 
endoplasmic reticulum and mitochondria of mammalian cells. These phases are also 
involved in biological processes such as membrane fusion, fat digestion and in the 
reorganization of cell membrane composition (Almsherqi, Z.A. et al. 2009; Erbes, J. et al. 
1994; Tresset, G. 2009). 
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4.2. AMP INTERACTION WITH LIPID MEMBRANES AS REVEALED BY MODEL STUDIES 
Regarding the interaction of antimicrobial peptides with membranes it is crucial to 
understand if AMPs are capable of altering the phospholipid phase behavior and in that 
case to correlate these possible changes in lipid polymorphism with models for the 
mechanism of action of AMPs. Using model membranes, namely liposomes (concentric 
bilayer vesicles) with different phospholipid compositions, and analyzing them by using 
different techniques (e.g. calorimetry, X-ray diffraction, spectroscopy), can give the 
desired information that enables the understanding of these changes and how they affect 
the overall structure and stability of the membrane. In this way the mechanism of action of 
AMPs could be clarified, and lead to a fine-tuning of new peptides in order to obtain a 
better therapeutic agent. The induction of cubic phases by AMPs, mostly by lowering the 
lamellar to non-lamellar phase boundary of lipid membranes, could mean that the peptide 
induces membrane disruption. Without disruption of the membrane, the formation of non-
lamellar phases can also alter the lipid domains in the cellular membrane that are 
important for many biological processes such endocytosis (induced by lipid rafts) or even 
the activity of membranar proteins that most of the time depend on these domains 
culminating into impairment of the membrane function (Lohner, K. 2009; Lohner, K. & 
Blondelle, S.E. 2005). 
Model membranes can be composed of different phospholipids, and as such their 
characteristics can be fine-tunned to the desired purpose of study. The compositions most 
widely used for the study of AMPs are: zwitterionic membranes of PC that mimics the 
erythrocytes membranes; the combination of PC and PG or PE with PG to try to mimic the 
cytoplasmic bacterial membrane that has a global negative charge. Recently much 
emphasis has been put on the use of POPE as the major class of phospholipids in the 
bacterial membrane whereas the amount of PC is more important in fungus. These are 
very simplified models of more complex structures, where the main aspect relies on 
changing the charge balance. Nevertheless, it is more and more clear that the AMPs are 
sensitive to the actual membrane composition, and thus efforts are also being made in 
biophysical studies to vary model membrane composition. More elaborated models can 
be used by the introduction of sphingomyelin and sterols for eukaryotic membranes and 
cardiolipin for prokaryotic membranes, or even by using membrane extracts of the 
bacteria. It should nevertheless be stressed that the main paradigm of model studies is to 
“keep it simple”, in order to enable discriminate analysis of interaction effects.  
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OBJECTIVES 
The objectives of this work were: 
1- To study the effects of the lactoferrin-derived peptides listed in table 4 (below) on 
Leishmania growth and viability. 
2- To study the effects of some lactoferrin-derived peptides listed in table 4 and of 
cecropin A-mellitin hybrid derivatives listed in table 3 (below) on the growth of 
Mycobacterium avium, both axenically and inside macrophages. 
3- To characterize the interaction of cecropin A-melittin derivatives CAM, K6 and K7 
(table 3) and lactoferrin-derived peptides LFcin17-30, LFampin265-284 and 
LFChimera (table 4) with lipid membranes by X-ray diffraction, using 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoethanolamine (POPE) model membranes. 
The work on the antimicrobial activity of AMPs against Leishmania was carried out at 
Centro Investigaciones Biológicas CIB/CSIC, Madrid, Spain, under the supervision of Luis 
Rivas. 
The work on Mycobacterium avium was carried out at Instituto de Biologia Molecular e 
Celular (IBMC), Porto, Portugal, under the supervision of Salomé Gomes. 
The studies on interaction with model membranes by X-ray diffraction were carried out at 
Faculdade de Ciências da Universidade do Porto, Portugal and Hasylab, DESY, Hamburg, 
Germany, under the supervision of Margarida Bastos. 
The cecropin A-melittin-derived peptides (table 3) were provided by David Andreu, 
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 
Barcelona, Spain (CA(1-7)M(2-9), K6 and K7), and by Paula Gomes, CIQ(UP), Faculdade 
Ciências da Universidade do Porto, Porto, Portugal (CA(1-7)M(2-9)). 
Table 3 – Properties of cecropin A-melittin-derived peptides.  
Peptide Sequence
a
 #AA Charge
b
 
CA(1-7)M(2-9) KWKLFKKIGAVLKVL 15 5+ 
K6 KWKLFK(Me3)KIGAVLKVL 15 5+ 
K7 KWKLFKK(Me3)IGAVLKVL 15 5+ 
a
 The C-terminals in all peptides are amidated; 
b 
Estimated net charge at neutral pH. 
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The peptides derived from lactoferrin (table 4) were provided by Jan Bolscher, ACTA, 
Department of Oral Biochemistry, Amsterdam, The Netherlands – LFampin265-284, 
LFcin17-30, LFChimera, and LFChimera surrogates. Paula Gomes, CIQ(UP), Faculdade 
Ciências da Universidade do Porto, Porto, Portugal, provided human lactoferricin 1-11 
(hLFcin1-11). 
The set of LFChimera surrogates (table 4) is composed by: LFChimera-R that differs from 
the parental hybrid peptide (LFChimera) in the order of the constituent peptides, instead of 
having LFcin17-30 bond to the α-carbon of an additional lysine and LFampin265-284 bond 
to the ε-carbon, we have the opposite situation; Di-LFcin and Di-LFampin, where the 
peptides are formed by two lactoferricins 17-30 and two lactoferrampins 265-284, 
respectively, also couple by an additional lysine in the same way as in LFChimera; and 
LFcin–LFampin and LFampin–LFcin, that are linear hybrids of lactoferricin 17-30 and 
lactoferrampin 265-284 coupled by a normal peptide bond, the only difference being the 
order of the peptides. 
Table 4 – Properties of lactoferrin-derived peptides. 
Peptide Sequence #AA Charge
a
 
LFcin17-30 FKCRRWQWRMKKLG 14 +6 
hLFcin1-11 GRRRRSVQWCA 11 +4 
LFampin265-284 DLIWKLLSKAQEKFGKNKSR 20 +4 
LFChimera 
FKCRRWQWRMKKLG        K 
 
DLIWKLLSKAQEKFGKNKSR 
35 +12 
LFChimera-R 
DLIWKLLSKAQEKFGKNKSR 
 
FKCRRWQWRMKKLG        K 
35 +12 
Di-LFcin  
FKCRRWQWRMKKLG        K 
 
            FKCRRWQWRMKKLG 
29 +14 
Di-LFampin  
DLIWKLLSKAQEKFGKNKSR       K 
 
          DLIWKLLSKAQEKFGKNKSR    
41 +10 
LFcin – LFampin  FKCRRWQWRMKKLG–DLIWKLLSKAQEKFGKNKSR 34 +10 
LFampin – LFcin  DLIWKLLSKAQEKFGKNKSR–FKCRRWQWRMKKLG 34 +10 
a
 Estimated net charge at neutral pH. 
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1. MATERIAL AND METHODS 
Peptides 
The lactoferrin-derived peptides tested for their antimicrobial activity against Leishmania 
were lactoferricin (LFcin17-30), lactoferrampin (LFampin265-284), LFChimera, and 
LFChimera surrogates described on table 4 of page 56. 
 
Leishmania donovani promastigotes 
Promastigotes of strain MHOM/SD/00/1S-2D (WT TURCO) of L. donovani were grown at 
26 ºC in RPMI 1640 (Gibco) pH=6.8, supplemented with 10% heat-inactivated fetal calf 
serum (HIFCS), 25 mM HEPES, 2 mM L-glutamine, 10 μg/mL gentamicin and 20 units/mL 
unicilin. 
Promastigotes of the WT TURCO-derived 3-Luc strain of L. donovani, which express a 
cytoplasmic form of luciferase (Luque-Ortega, J.R. et al. 2001), were grown in the same 
conditions as the wild-type strain, except for the addition of 30 μg/mL geneticin to the 
medium. 
 
Leishmania pifanoi amastigotes 
Amastigotes MHOM/VE/60/Ltrod of L. pifanoi were grown at 32 ºC in M199 pH=7.2, 
supplemented with 20% HIFCS, 5% trypticase, 13.8 mM glucose, 76 μM hemin and 48 
μg/mL gentamicin. 
 
Leishmania harvesting 
The parasites were collected at late exponential growth phase by centrifugation (2000 rpm, 
10 min, 4 ºC). The supernatant was discarded carefully and the cells were washed twice 
with Hank’s Balanced Salt Solution (HBSS: 137 mM NaCl, 5.3 mM KCl, 0.4 mM KH2PO4, 
4.2 mM NaHCO3 and 0.4 mM Na2HPO4, pH=7.2, supplemented with 10 mM D-glucose) at 
4ºC. Cells were resuspended in the same buffer at final density of 4x107 cells/mL or 2x107 
cells/mL, and kept on ice until use.  
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Determination of antimicrobial activities 
Principles 
The antimicrobial activity of the different peptides was determined by colorimetric 
measurement of the reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to blue insoluble formazan by mitochondrial reductases. 
When cell viability is impaired, this leads to a decrease in formazan formation; by the 
same rule, when tested on parasite proliferation, the amount of formazan is proportional to 
the number of viable cells.  
This method can be applied to assess the impact of an antimicrobial peptide on cell 
viability (short-term effect) and on the cell proliferation (long-term effect), using the same 
sample, and determine parameters like the IC50 (the concentration of AMP that inhibits 
50% of MTT reduction at the end of 4h) and the LD50 (lethal concentration that causes 
50% inhibition of parasite proliferation at the end of 3 or 5 days, for promastigotes and 
amastigotes, respectively) (Luque-Ortega, J.R. & Rivas, L. 2010). 
Method 
Parasite suspension (4x107 cells/mL) was distributed (60 μL/well) in a sterile 96-well 
microplate; 60 μL of the corresponding peptide solution (all the solutions and suspensions 
in HBSS + 10 mM glucose) was added to the respective well, and incubated for 4h at 26 
ºC or 32 ºC, for promastigotes and amastigotes, respectively.  
Long-term effect: 
- For promastigotes, after 4h of incubation 20 μL of each well were transferred into a 
new 96-well microplate with 130 μL/well of RPMI 1640 without phenol red + 10% 
HIFCS, and incubated at 26 ºC, for 3 days, to allow parasite proliferation. At the end of 
the incubation, 50 μL of 2 mg/mL MTT solution was added to each well and further 
incubated at 26 ºC (protected from light) until colour development. Finally, to stop the 
reaction and to dissolve the blue formazan crystals, 50 μL of SDS 10% was added to 
each well. Absorbance was read at 600 nm in a microplate reader (Bio-Rad model 680) 
fitted with a 595 nm filter.  
- For amastigotes, in the end of the incubation, 20 μL of each well were transferred to a 
new 96-well microplate with 130 μL/well of M199 + 10% HIFCS, and incubated at 32 ºC, 
for 5 days, to allow parasite proliferation. Afterwards, the content of each well was 
transfer into 1.5 mL microcentrifuge tubes, and wells were additionally washed with 100 
μL of HBSS. The tubes were centrifuged and washed again with 1 mL of HBSS. The 
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pellet was resuspended in 100 μL of 0.5 mg/mL MTT solution, and the whole content of 
the tubes was transferred into a new 96-well microplate and MTT reduction carried out 
as described previously.  
For the short-term assay, after incubation with the respective peptide, 100 μL of MTT (1 
mg/mL) solution were added to each well of the plate incubated for 4h, and proceeded as 
described before.  
The parameters IC50 and LD50 were calculated using the SigmaPlot® software, and the 
results represented as the media of at least two independent experiments (conditions 
tested in triplicates) with the corresponding standard deviation (SD) indicated. 
 
Real-time monitoring of in vivo changes in intracellular levels of ATP in L. donovani 
promastigotes 
Principles 
A strain of L. donovani promastigote, 3-Luc that express a cytoplasmic form of luciferase 
was used to monitor the levels of intracellular ATP. This assay is based on the reaction, 
catalyzed by luciferase that converts D-luciferin into D-oxoluciferin in the presence of O2, 
with consumption of one molecule of ATP and emission of one foton. To overcome the 
low permeability of the cellular membrane to D-luciferin at physiological pH, a caged ester 
analogue of luciferin, DMNPE-D-luciferin (D-luciferin, 1-(4,5-dimethoxy-2-nitrophenyl) 
ethyl ester), free-permeable to the membrane, was used. Once inside the cytoplasm D-
luciferin is released by intracellular esterases. In this case, luminescence is directly 
related to the cytoplasmic levels of free-ATP, the limiting substrate for the reaction 
(Luque-Ortega, J.R. et al. 2003). 
When the cells are intact, and in the presence of luciferase substrate, cells emit light. 
However in the presence of a peptide that induces membrane damages, the loss of ionic 
gradient or, for larger lesions, leakage of ATP, with subsequent depletion in the cytoplasm, 
will lead to the decrease of the light emitted (Luque-Ortega, J.R. et al. 2003). 
Method 
Parasites, L. donovani 3-Luc promastigotes, were resuspended at 2x107 cells/mL in HBSS 
+ 10 mM glucose, incubated at 26 ºC with DMNPE-D-luciferin (25 μM, final concentration), 
and 90 μL of the suspension was distributed into a black 96-well microplate. When 
luminescence reached a plateau, 10 μL of the respective peptide was added (t = 0) and 
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the decay on the luminescence was monitored in a BMG Polarstar Galaxy microwell 
reader (Öffenburg, Germany) equipped with luminescence setting. Luminescence data 
were referred as percentage of luminescence corrected with the corresponding values of 
untreated promastigotes.  
 
Plasma membrane permeabilization of L. donovani promastigotes 
Principles 
The presence of a peptide may induce lesions into the cytoplasmic membrane large 
enough to allow entrance of the cationic vital dye, Sytox Green (MW = 600 Da), to which 
intact cells are impermeable. Once the dye gains access to the intracellular space, it binds 
to nucleic acids with high-affinity, close to irreversibility in practical terms. This enhances 
its fluorescence more than 500-fold (Luque-Ortega, J.R. & Rivas, L. 2010). So the 
increase in fluorescence stands for the severity of the damage to the parasites 
membranes.  
Method 
Two different assays were performed to assess the entrance of the vital dye: 
- First, the parasites L. donovani promastigotes (90 μL at 2x107 cells/mL) were incubated 
with Sytox Green (1 μM, final concentration) in HBSS + 10 mM glucose and 
fluorescence changes were monitored at λex = 504 nm and λem = 524 nm in a BMG 
Polarstar Galaxy microwell reader (Öffenburg, Germany), immediately after adding 10 
μL of the corresponding peptide solution (t = 0). The results were expressed as 
percentage relative to full permeabilized cells achieved by the addition of 0.1% Triton 
X-100.  
- Second, to assess the incorporation of the dye into individual parasites, L. donovani 
promastigotes and antimicrobial peptides were incubated at the same conditions as 
described above, except that the Sytox Green was added only after 4h of incubation at 
26 ºC, and the fluorescence was measured by cytofluorometry in a Beckman-Coulter 
FC-500 Analyzer. Maximal permeation was achieved by 15 μM of digitonin in order to 
preserve parasite shape.  
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AMPs or CPPs: Confocal Microscopy 
To evaluate whether the peptides enter the cells without permeabilizing the membrane 
and extrapolate if these peptides had an internal target to account for their lethal action, in 
other words, whether they behaved or not as Cell-Penetrating Peptides (CPPs) L. 
donovani promastigotes and L. pifanoi amastigotes (4x107 cells/mL) were incubated with 
the peptides labeled with FITC (fluorescein isothiocyanate) in HBSS + 10 mM glucose for 
4h at 26 ºC and 32 ºC for promastigotes and amastigotes, respectively. After 4h of 
incubation propidium iodide, PI, (50 μg/mL, final concentration) was added to the cells. A 
15 μL drop of each sample was placed in microscope slides previously coated with poly-
lysine (to favour parasite attachment and immobilization) and parasites were observed 
and photographed in a Confocal Laser Scanning Microscope Leica TCS – SP2 ABOS. 
 
Ultrastructural alterations: Transmission Electron Microscopy 
L. donovani promastigotes or L. pifanoi amastigotes suspension (4x107 cells/mL) in HBSS 
+ 10 mM glucose were incubated with the peptides for 4h at 26 ºC or 32 ºC, for 
promastigotes and amastigotes, respectively. After the incubation, cells were washed with 
PBS and resuspended in a 3% glutaraldehyde solution in PBS for 1-2h, for cell fixation, 
and then incubated with 2.5% osmium tetroxide (OsO4) for about the same time (1-2h), 
with PBS washes between steps. Cells were dehydrated by successive incubations with 
increasing concentrations of ethanol: 30% and 50% for 30 min; 70% overnight; 90% and 
100% for 30 min. At the end, parasites were incubated with propylene oxide and 
afterwards, propylene oxide was successively replaced by a mix of resins 3A / 7B (resin A: 
6.88 mL of Epon-812 epoxy resin + 11.11 mL of dodecenyl succinic anhydride (DDSA) – 
resin B: 22 mL of Epon-812 epoxy resin + 19.8 mL of methyl -5-norbornene-2,3-
dicarboxylic anhydride (NMA)). The protocol consisted in successive incubations with 
different ratios of a mixture between propylene oxide and the resins: 3:1 and 1:1 for 30 
min, 1:3 overnight and 0:1 for 30 min. The inclusion of cells into the resins was completed 
with a polymerization step (70ºC for 48h), catalyzed by the addition of 1.8% 2,4,6-
tri(dimethylamino methyl) phenol (DMP30) as accelerator. The samples were distributed 
into electron microscopy capsules (Size 3, Agar Scientific, Stanted, England) that were 
trimmed and sliced with an ultramicrotome LKB. Sections were placed into formvard-
carbon-coated copper grids and stained with 25 mM lead citrate. The samples were 
observed and photographed in a transmission electron microscope JEOL-1230. 
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Colocalization of antimicrobial peptides and L. pifanoi amastigotes in peritoneal 
macrophages: Confocal microscopy  
Three days (day 0) prior to macrophage harvesting, BALB/c mice were intraperitoneally 
(i.p) injected with 1 mL of 10% thioglycolate. On the 3rd day, mice were sacrificed by 
cervical dislocation, and macrophages were obtained by washing the peritoneum twice 
with warm PBS. 100 000 cells/well were seeded in a Lab-Tek 16-well chamber slide 
system, with RPMI 1640 + 10% HIFCS. Macrophages were incubated for 2-3h at 37 ºC to 
allow cell attachment to the glass bottom of the chamber slide.  
When the macrophages were well attached to the coverslides, the medium was replaced 
with a suspension of L. pifanoi amastigotes in fresh medium, at a final ratio 
amastigote:macrophage of 3:1 and incubated for at least 4h at 32 ºC. Next, non 
phagocytized parasites were removed by washing each well twice with warm PBS, and 
substituted for new media (RPMI 1640 + 10% HIFCS) with or without peptides at different 
concentrations. To ascertain whether FITC-labeled peptides, have any privileged 
subcellular accumulation inside the infected macrophages, including the parasitophorus 
vacuole where the Leishmania amastigotes grow, macrophages, previously seeded in a 
Lab-Tek 16-well chamber slide system, were incubated with the labeled peptides 
overnight. After that, wells were washed twice with warm PBS. The plastic wells, and any 
trace of silicone gasket, were removed from the slide carefully according to the 
manufacturer instructions. Before covering the slide with a coverslide, a drop of PBS was 
placed in the middle of each preparation to avoid cell drying. Finally macrophages were 
observed and photographed in a Confocal Laser Scanning Microscope Leica TCS – SP5 
ABOS. 
 
Determination of macrophage viability 
To measure macrophage viability in the presence of different peptide concentrations, 
mouse peritoneal macrophages were seeded (100 000 cells/well) into a 96-well plate. 
After adherence to the plate, macrophages were incubated, for 4h in 100 μL of HBSS + 10 
mM glucose with or without peptides at different concentrations. After peptide incubation, 
100 μL of 1 mg/mL MTT solution was added to each well, and MTT reduction was 
measured as described before.  
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2. RESULTS 
2.1. Determination of the antimicrobial activity of lactoferrin-derived peptides 
against L. donovani promastigotes and L. pifanoi amastigotes 
Lactoferrin-derived peptides, LFcin17-30, LFampin265-284 and LFChimera were all 
leishmanicidal (determined by MTT reduction) against L. donovani promastigotes below 
50 μM (table 5). LFChimera was the most active, with IC50 and LD50 values around 4 μM 
(table 5). All the peptides were less active against amastigotes than promastigotes. LFcin 
and LFampin had IC50 and LD50 values above 50 μM against amastigotes while the 
LFChimera was once again more active, with IC50 and LD50 values below 10 μM (table 5). 
Leishmania parasites were not able to recover from the damage induced by the peptides 
after 4h of incubation (represented by IC50), as the LD50 was always similar to the IC50, for 
both promastigotes and amastigotes (table 5).  
The inhibitory activity of LFChimera was always higher than the sum of its separated 
components (figure 21), stressing the importance of having the peptides bond to each 
other. 
Table 5 – Leishmanicidal activity of LFcin17-30, LFampin265-284, LFChimera and 
LFChimera surrogates against L. donovani promastigotes and L. pifanoi amastigotes. The 
values correspond to the concentration causing 50% inhibition of MTT reduction. Each value 
represents the average and standard deviation of at least two independent experiments. 
AMP 
L. donovani promastigotes L. pifanoi amastigotes 
IC50 / μM LD50 / μM IC50 / μM LD50 / μM 
LFcin17-30 21.4 ± 1.3 25.7 ± 1.4 > 50 > 50 
LFampin265-284 29.1 ± 1.7 33.2 ± 1.5 > 50 > 50 
LFChimera 3.7 ± 0.4 3.6 ± 0.1 6.0 ± 1.1 4.7 ± 1.1 
LFChimera-R 3.5 ± 0.1 2.6 ± 0.4 4.2 ± 0.3 3.6 ± 1.1 
Di-LFcin 2.4 ± 0.1 2.1 ± 0.2 3.4 ± 0.6 3.2 ± 0.6 
Di-LFampin  4.4 ± 0.1 4.0 ± 0.4 4.8 ± 0.8 5.9 ± 1.4 
LFcin – LFampin  3.9 ± 0.1 3.4 ± 0.2 4.8 ± 0.6 4.9 ± 1.2 
LFampin – LFcin  1.6 ± 0.1 1.6 ± 0.1 1.5 ± 0.3 0.73 ± 0.02 
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Figure 21 – Effect of lactoferrin-derived peptides on the viability of L. donovani 
promastigotes. Parasites were incubated with different concentrations of LFcin17-30, 
LFampin265-284, LFChimera, and with its two constituent peptides together, for 4h in HBSS + 10 
mM glucose. The viability of the parasites was measured by MTT reduction. The results of one 
representative experiment out of three are shown. 
In order to determine structure-activity relationships for LFChimera, a set of LFChimera 
surrogates was tested along with the parental hybrid peptide. In preliminary experiments, 
the IC50 and LD50 of these peptides against L. donovani promastigotes and L. pifanoi 
amastigotes were determined by MTT reduction. All the surrogates tested had an activity 
similar to that of LFChimera, except for two peptides that were even more active, Di-LFcin 
and LFampin-LFcin (table 5). This last one was active below 2 μM against both forms of 
the parasite (table 5). An interesting fact was that all peptides had similar activities on 
promastigotes and on amastigotes, which was not observed for LFChimera. So, the 
attempt to reach structure-activity relationships is not yet fully accomplished, as the 
experiments so far were limited to the small number of surrogates available, and further 
experiments with different surrogates to obtain deeper information about structure-activity 
relationships are already planned. Nevertheless, some preliminary conclusions can be 
drawn: i) it seems that the presence of two lactoferricins 17-30 (Di-LFcin) improves the 
activity of the peptide due to a higher charge (+14 compared to +12 of LFChimera and to 
+10 of Di-LFampin); ii) the fact that a linear hybrid, LFampin-LFcin, has higher activity 
than LFChimera suggest that the link between the LFcin and LFampin through a 
additional lysine is not crucial for the antimicrobial activity of the parental hybrid peptide. 
Moreover in these linear peptides it seems important the order of the constituent peptides, 
as LFampin-LFcin was more active than LFcin-LFampin. Due to the finding of at least two 
very promising peptides, that could be used in the future to fight leishmaniasis, further 
experiences will be performed with these LFChimera surrogates to uncover their 
mechanism of action and cytotoxicity. 
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2.2 Evaluation of Leishmania plasma membrane permeabilization by lactoferrin-
derived peptides 
In order to test whether the lethal mechanism of lactoferrin-derived peptides against 
Leishmania correlates with a plasma membrane permeabilization process, a set of 
permeabilization assays were performed. These experiments can elucidate on how these 
peptides act, the time-frame of action, what is the main target, among others. 
First the intracellular levels of free-ATP in living parasites, L. donovani promastigotes, 
were monitored. Immediately after peptide addition (t=0) there was a fast and dose-
dependent bioenergetic collapse of the parasites (figure 22). This means that the 
presence of the peptide disturbs the membrane, impairing the production of ATP by the 
parasites, due to loss of the ionic gradient or leakage of ATP, leading to their death. Once 
again the effect of LFChimera was stronger, as for much lower concentrations (between 
10 and 1.25 μM) a similar or even higher effect was observed, when compared with the 
other two peptides. 
 
Figure 22 – Real-time depletion of intracellular ATP levels upon peptide addition in living L. 
donovani 3-Luc promastigotes. Measurement of intracellular levels of ATP, by luminescence, in 
L. donovani 3-Luc promastigotes after peptide (LFcin17-30, LFampin265-284 and LFChimera) 
addition at t = 0 (luminescence = 100%). The results of one representative experiment out of two 
are shown as percentage relative to control parasites (without the addition of AMPs). 
With the above results, it was recognized that these peptides induce membrane damages. 
However how severe were those damages? Are they big enough to let a cationic molecule, 
Sytox Green, with 600 Da to enter inside the cytoplasm? To answer these questions the 
entrance of Sytox Green was monitored, after adding the peptide, by the fluorescence 
enhancement, due to the binding of the dye to nucleic acids. The results obtained were 
similar and in agreement with the luminescence results. It was possible to see a fast and 
dose-dependent uptake of the dye that reaches saturation minutes after peptide addition 
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(figure 23). Once more, LFChimera was much more active than its separated components, 
reaching 100% of dye entrance (all cells are dead) at 10 μM, whereas the other two 
peptides at this concentration only cause approximately 20% of dye entrance. 
The kinetic behavior of LFcin17-30 was very peculiar, and different from the other 
peptides (figure 23). The entrance of the dye was much slower, revealing that the fast 
bioenergetic collapse of the parasites when in contact with this peptide is probably due 
first to loss of the ionic gradient and only later to leakage of ATP, which requires larger 
membrane damages, the same ones that allows Sytox entrance to the cells. 
 
Figure 23 – Permeabilization of the plasma membrane of L. donovani promastigotes by 
lactoferrin-derived peptides measured by the entrance of a vital dye. Kinetics of Sytox Green 
entrance after peptide (LFcin17-30, LFampin265-284 and LFChimera) addition (t = 0; fluorescence 
= 0), measured by the increase of fluorescence after binding of the dye to intracellular nucleic acids 
(λex = 504 nm; λem = 524 nm). The results of one representative experiment out of two are shown 
and the values were expressed as percentage relative to full permeabilized cells (with 0.1% of 
Triton X100). 
The binding of Sytox Green to nucleic acids is practically irreversible, so once the 
saturation is reached, even if the cell recovers from the damages this will not be reflected 
on the levels of fluorescence (if the assay is conducted under the above conditions). So, 
another assay was performed with this dye, but instead of adding at time zero, Sytox 
Green was added after 4h of incubation of cells with the peptides at different 
concentrations. In figure 24, it can be seen that the accumulation was not due to transitory 
disruptions of the membrane, as fluorescence is cumulative, but that the lesion was 
present and parasites were not able to recover from the damages induced in the first 
minutes (both assays of uptake of vital dyes are highly concordant) and the amount of 
labeled cells were in agreement with results obtained for the IC50 (also determined at the 
end of 4h). 
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A deeper insight into the results, shows that parasites treated with LFcin17-30 seem to 
form aggregates, as two different populations that incorporated the dye (populations that 
are shifted to the right in comparison with the control population – 0 μM – in green), aside 
from the one unlabeled, were distinguished (figure 24). 
LFChimera, according to the previous results, was much more active. The results showed 
two different types of populations (figure 24), a minor one, essentially unlabeled, that 
diminishes as the concentration of LFChimera increases, and a major one, which 
increases with peptide concentration, but without shift of its fluorescence levels 
(abscissa’s axis) a situation suggesting an all-or-none effect of the peptide. 
 
Figure 24 – Permeabilization of L. donovani promastigotes plasma membrane by lactoferrin-
derived peptides measured by the entrance of vital dyes. Cell incorporation of Sytox Green, 
after 4h of incubation, with different concentrations of the peptides LFcin17-30, LFampin265-284 
and LFChimera, as measured by cytofluorometry. Full permeabilization was achieved with 15 μM 
of digitonin. The results of one representative experiment out of three are shown. 
To evaluate whether these peptides may act as CPPs (entering the cells without killing 
them and acting in an intracellular target) the incorporation of labeled peptides with FITC 
into parasites was evaluated by confocal microscopy. L. donovani promastigotes and L. 
pifanoi amastigotes were incubated for 4h with LFcin17-30-FITC, LFampin265-284-FITC 
and LFChimera-FITC. At the end of the experiment, propidium iodide, that only enters into 
severely damaged or dead cells, was added. For both forms of the parasites, the 
conclusion was the same, all cells labeled by the respective peptide (green) were also 
dead (red) (figure 25 and 26). In other words, it was not possible to spot green labeled 
cells alive. This observation was quite evident for L. pifanoi amastigotes, as for the first 
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two peptides, both live and dead cells are seen, but only the dead cells are labeled in 
green (figure 26). So these peptides act with a mixed mechanism by which membrane 
permeabilization appears to be the main effect, although the presence of peptides inside 
the cells may suggest the existence of possible intracellular targets. 
For LFcin17-30 cell aggregates were visible (figure 25), which reinforces the theory that 
this peptide induces cellular aggregation (already seen by cytofluorometry) probably due 
to is charge (+6) and the anionic character of Leishmania membrane (Bolscher, J.G.M. et 
al. 2009; Wassef, M.K. et al. 1985). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 – Permeabilization of L. donovani promastigotes plasma membrane by lactoferrin-
derived peptides assessed by fluorescence microscopy. L. donovani promastigotes were 
incubated for 4h with lactoferrin-derived peptides labeled with FITC and at the end of the incubation, 
propidium iodide (PI) was added. Cells were photographed in a Confocal Laser Scanning 
Microscope Leica TCS – SP2 ABOS with final magnification of 630x, and representative pictures 
are shown. Upper panels show phase contrast and bottom panels the corresponding fluorescence 
image. A) 10 μM LFcin17-30-FITC, B) 20 μM LFampin265-284-FITC and C) 5 μM LFChimera-FITC. 
 
 
A       B         C 
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Figure 26 – Permeabilization of L. pifanoi amastigotes plasma membrane by lactoferrin-
derived peptides assessed by fluorescence microscopy. L. pifanoi amastigotes were incubated 
for 4h with lactoferrin-derived peptides labeled with FITC and finally propidium iodide (PI) was 
added. Cells were photographed in a Confocal Laser Scanning Microscope Leica TCS – SP2 
ABOS with final magnification of 630x, and representative pictures are shown. Upper panels shows 
phase contrast and bottom panels the corresponding fluorescence image. A) 20 μM LFcin17-30-
FITC, B) 35 μM LFampin265-284-FITC and C) 5 μM LFChimera-FITC. 
Transmission electron microscopy (TEM) is a useful technique to identify morphological 
damages on the parasites after their incubation with peptides. In this work, L. donovani 
promastigotes were incubated with 5 μM LFChimera and cells were observed in a 
transmission electron microscope. By analyzing the obtained pictures (figure 27), it may 
be concluded that the peptide induced in most of the parasites, cytoplasmic vacuolation, 
loss of definition of the organelles, and a massive leakage of intracellular material (figure 
27 – red arrows), whereas some cells appear healthy with no visible damages (figure 27 – 
green arrows), suggestion once again an all-or-none effect. 
 
 
 
A       B         C 
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Figure 27 – Assessment of morphological damages of L. donovani promastigotes incubated 
with LFChimera. Parasites incubated with 5 μM LFChimera for 4h were observed and 
photographed in a transmission electron microscope. Representative pictures are shown. Red 
arrows – damaged cells; green arrows – healthy cells. 
2.3 Effect of lactoferrin-derived peptides on L. pifanoi-infected macrophages. 
Leishmania parasites, namely amastigotes, live inside mononuclear phagocytic cells of a 
wide variety of mammals. So, it is important to know what are the effects of lactoferrin-
derived peptides on macrophages. 
The toxicity of the three peptides towards non-infected peritoneal macrophages, was 
determined by MTT reduction, when the cells were incubated with the peptides for 4h in 
buffer (HBSS + 10 mM glucose). LFChimera showed a high cytotoxicity activity when 
compared with the other two peptides which did not reach 50% of loss of cell viability up to 
50 μM (figure 28). 
 
 
 
 
Figure 28 – Toxicity of lactoferrin-derived peptides towards peritoneal macrophages. Non-
infected peritoneal macrophages were treated with different concentrations of LFcin17-30, 
LFampin265-284 and LFChimera, for 4h in HBSS + 10 mM glucose, and macrophage viability was 
determined by MTT reduction. 
The ability of the peptides to reach intracellular amastigotes (which live inside 
macrophage vacuoles) as well as their overall subcellular localization, was determined by 
incubating macrophages infected with L. pifanoi amastigotes, with LFcin17-30-FITC, 
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LFampin265-284-FITC and LFChimera-FITC. Due to a limited number of macrophages, 
only one concentration of each peptide was tested. The choice was made according to the 
results of toxicity by choosing the highest concentration with lower toxicity (preferably 
below 20%). LFcin17-30 at 20 μM colocalized with the intracellular amastigotes, whereas 
LFampin265-284 at 50 μM and LFChimera at 5 μM, were able to enter into the 
mammalian cell but do not colocalize with the parasites (figure 29). Further experiences 
will be done to evaluate the colocalization with different concentration of peptides and with 
different times of incubation. Interestingly, in these experiments the peptides did not seem 
to be toxic to the macrophages at the tested concentrations, as the cell morphology was 
not affected (figure 29). When macrophages were treated with peptides for localization 
experiments, the assays were performed in full-medium (RPMI 1640 + 10% HIFCS) and 
not in buffer, as was the case with MTT reduction assays. Because the full-medium, 
contains HIFCS, as well as proteolytic enzymes, the activity of the peptides, may be 
distinct from that in HBSS buffer. Preliminary experiments were performed to assess 
toxicity of the peptides in full-medium but no conclusive results were obtained. 
 
 
 
 
 
 
 
 
 
 
Figure 29 – Colocalization of lactoferrin-derived peptides and L. pifanoi amastigotes in 
peritoneal macrophages. Infected macrophages with L. pifanoi amastigotes and incubated, 
overnight, with lactoferrin-derived peptides labeled with FITC were photographed in a Confocal 
Laser Scanning Microscope Leica TCS – SP5 ABOS with final magnification of 630x, and 
representative pictures are shown. Upper panels show phase contrast, and bottom panels the 
corresponding fluorescence image. A) 20 μM LFcin17-30-FITC, B) 50 μM LFampin265-284-FITC 
and C) 5 μM LFChimera-FITC. 
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derived and lactoferrin-derived 
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1. MATERIAL AND METHODS 
Peptides 
In the evaluation of the activity against Mycobacterium avium, the following peptides were 
used: cecropin A-melittin derivatives CA(1-7)M(2-9) or CAM, K6 and K7 (described in 
table 3, page 55) and lactoferrin-derived peptides hLF1-11, LFcin17-30, LFampin265-284 
and LFChimera (described in table 4, page 56). 
 
Bacteria  
M. avium strain 2447, smooth transparent variant (SmT) was isolated from an AIDS 
patient and provided to us by Dr. F. Portaels (Institute of Tropical Medicine, Antwerp, 
Belgium). 
Mycobacteria were grown to mid-log phase in Middlebrook 7H9 medium (Difco, Sparks, 
MD) containing 0.05% of Tween 80 (Sigma, St. Louis, MO) and 10% of ADC supplement 
(Albumin-Dextrose-Catalase) at 37 ºC. Bacteria were harvested by centrifugation, washed 
twice with saline containing 0.04% Tween 80, resuspended in the same solution and 
briefly sonicated in order to disrupt bacterial clumps. The suspension was stored in 
aliquots at -80 ºC until use. Just before use, an aliquot was quickly thawed and diluted to 
the appropriate concentration. 
 
Effect of antimicrobial peptides on the viability of M. avium in axenic cultures  
Principles 
To determine the direct effect of the antimicrobial peptides on M. avium 2447 SmT in 
axenic cultures (bacteria growing in liquid medium), three different methods were used. 
First the bacterial growth was monitored by optical density at 600 nm. When they were in 
the exponential phase of growth, the viability of M. avium was quantified by resazurin 
reduction and by colony forming units (CFUs). 
Resazurin is a blue oxidation-reduction indicator (Palomino, J.C. et al. 2002) which is non-
fluorescent until it is reduced to the pink colored and highly fluorescent resorufin. 
Resazurin reduction can be used to measure cellular viability, as only viable cells can 
reduce this dye and the level of resazurin reduction is proportional to the number and 
viability of the cells present. This is a simple and non-destructive assay, that can be 
 80 
 
applied both to adherent and non-adherent cells, and it complements and gives 
comparable data with the colony forming units (CFUs) assay (Anoopkumar-Dukie, S. et al. 
2005). 
Method 
M. avium 2447 SmT was grown in Middlebrook 7H9 medium to exponential phase. 107 
CFU of bacteria were seeded per well into 96-wells flat bottom plates and incubated with 
the peptides in a final volume of 200 μL. Each peptide concentration was tested in 
triplicates. The plates were incubated at 37 ºC in a humid atmosphere. At the 6th day of 
culture, 10 μL of 2.5 mM resazurin was added to each well and after 24h of incubation the 
fluorescence was measured in a Gemini XM plate fluorometer (Molecular Devices) (λex = 
560 nm; λem = 590 nm). The results were expressed as percentage of the fluorescence 
obtained in control wells without peptides. 
% mycobacterial cell viability = 
relative fluorescence intensity in experimental wells
relative fluorescence intensity in control wells
 x 100 
 
In some of the assays, after 7 days of incubation, the viability of the bacteria was also 
measured by a colony forming units (CFUs) assay (using the same wells as the resazurin 
assay). The bacterial suspension in each well was serially diluted in water containing 
0.04% Tween 80. The dilutions were plated in Middlebrook 7H10 agar medium (Difco, 
Sparks, MD), supplemented with OADC (Oleic acid-Albumin-Dextrose-Catalase) and the 
number of colonies was counted after 7 days at 37 ºC. The difference, in terms of log10 
CFU/mL between the first and the last day of incubation was designated “log increase”. 
log increase CFU/mL = log10 CFU/mL (day 7) – log10 CFU/mL (day 0) 
 
Collection, infection and treatment of Bone Marrow derived Macrophages (BMMØ)  
Macrophages were derived from the bone marrow of BALB/c INF-γ knock-out mice. Each 
femur and tibia was flushed with 5 mL of Hank’s Balanced Salt Solution (HBSS, Gibco, 
Paisley, U.K.). The cell suspension was centrifuged and resuspended in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Gibco, Paisley, U.K.) supplemented with 10 mM 
glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 10% Fetal Bovine Serum (FBS, Gibco, 
Paisley, U.K.) and 10% of L929 cell conditioned medium (LCCM) as a source of 
Macrophage Colony Stimulating Factor (M-CSF).  
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Cells were cultured overnight at 37 ºC in a 7% CO2 atmosphere to remove fibroblasts. 
Non-adherent cells were collected with cold HBSS medium, washed and seeded at the 
concentration of 5x105 cells/well in 24-wells culture plates (Nunc, Gibco). In some cases 
LPS-free round glass coverslips were placed at the bottom of culture wells, so that 
macrophages could adhere to this coverslip and later be observed by confocal microscopy. 
The plates were incubated at 37 ºC in a 7% CO2 atmosphere. Four days after seeding, 
10% of LCCM was added to the culture medium and on the 7th day, the medium was 
renewed. At day 10 of culture, when the cells are fully differentiated into macrophages, 
each well was incubated with 106 CFU of M avium 2447 SmT in DMEM, for 4h at 37 ºC in 
a 7% CO2 atmosphere. After incubation, cells were washed several times with warm 
HBSS to remove non-internalized bacteria, and re-incubated with new medium, DMEM 
with 10% FBS and 10% LCCM, with or without different concentrations of peptides alone 
or in combination with different antibiotics. Each condition was tested in triplicates. 
After 4 or 7 days of infection, the intracellular growth of M. avium 2447 SmT was 
evaluated by colony forming units (CFUs). Macrophages were lysed, using 0.1% saponin. 
The bacterial suspensions were serially diluted in water containing 0.04% Tween 80 and 
plated in Middlebrook 7H10 agar medium supplemented with OADC. The number of 
colonies was counted after 7 days at 37 ºC. The difference, in terms of log10 CFU/well 
between the first and the last day of culture was designated “log increase”. 
log increase CFU/well = log10 CFU/well (day 4 or 7) – log10 CFU/well (day 0) 
 
Determination of macrophage viability  
Principles 
The viability of infected macrophages was determined by resazurin reduction (see above) 
and by the use of VibrantTM Cytotoxicity Assay Kit V-23111 (Molecular Probes) (both 
assays can be performed using the same wells). 
The cytotoxicity assay kit monitors the release of the cytosolic enzyme glucose 6-
phosphate dehydrogenase (G6PD) from damaged cells into the surrounding medium. This 
enzyme is detected in cell culture supernatants by a two-step enzymatic process that 
leads to the reduction of resazurin (figure 30), and the resulting fluorescence signal is 
proportional to the amount of G6PD released which in turn correlates with the number of 
dead cells in the sample.  
 
 82 
 
 
 
 
 
 
Figure 30 – Principle of the coupled enzymatic assay for detection of glucose 6-phosphate 
dehydrogenase activity. Oxidation of glucose 6-phosphate by glucose 6-phosphate dehydrogenase 
results in the generation of NADPH, which in turn leads to the reduction of resazurin by diaphorase 
to yield fluorescent resorufin (Molecular Probes). 
 
Method 
Resazurin reduction as a measure of cell viability: After 4 or 7 days of infection and 
peptide treatment, 100 μL of resazurin 1.25 mM was added to each well. The plates were 
incubated for 4h at 37 ºC in a 7% CO2 atmosphere. In the end, the fluorescence was 
measured in a Gemini XM plate fluorometer and expressed as percentage of the 
fluorescence obtained in control wells (non-treated infected macrophages). 
% macrophage viability = 
relative fluorescence intensity in treated infected macrophages
relative fluorescence intensity in non-treated infected macrophages
 x100 
 
VibrantTM Cytotoxicity Assay Kit to measure cell death: After 2 days of infection and 
peptide treatment 50 μL of the supernatant of each well was transferred into a new 96-
wells flat bottom plate. An enzymatic mixture was prepared according to manufactor’s 
instructions and added to the wells. Fluorescence readings (λex = 530 nm; λem = 590 nm) 
were taken at 5 minutes intervals at 37 ºC. The relative fluorescence intensity obtained for 
experimental cells (treated infected macrophages) and for fully lysed cells, was corrected 
by subtracting the values obtained from the untreated infected macrophages. The relative 
cytotoxicity was determined by dividing the corrected fluorescence intensity of 
experimental cells by the corrected fluorescence intensity of fully lysed cells.  
% cytotoxicity = 
corrected fluorescence intensity of experimental cells
corrected fluorescence intensity of fully lysed cells
 x 100 
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Confocal Microscopy 
At day 3rd of infection, macrophages that were cultured in glass coverslips, were washed 
with warm PBS and fixed with 4% paraformaldehyde (Merck) in PBS supplemented with 
120 mM sucrose for 30 min at room temperature. For fluorescence quenching, cells were 
incubated with PBS containing 50 mM of NH4Cl, for 10 min. Cells were washed again with 
PBS and incubated with Auramine O stain kit (Polysciences, Inc.). Briefly, cells were 
incubated with a few drops of Auramine O for 15 minutes (without letting the surface dry 
and protected from light), then with fluorescent decolorizer, for 30-60 seconds, and finally 
with potassium permanganate for 2 minutes. Between incubations cells were washed with 
distilled water. Slides were mounted using Mowiol (Polyscience) and sealed with nail 
polish. Macrophages were observed and photographed in a Laser Scanning Confocal 
Microscope Leica SP2 AOBS SE (Leica Microsystems, Germany). 
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2. RESULTS 
2.1. Cecropin A-melittin-derived peptides 
2.1.1. Effect on M. avium viability in axenic cultures 
Cecropin A-melittin hybrid, CA(1-7)M(2-9) or CAM, and the respective trimethylated 
derivatives K6 and K7, had a direct effect against M. avium, significantly inhibiting its 
growth in liquid medium above 50 μM. However, even at four-fold higher concentration 
(200 μM) the growth inhibition did not reach 50% (figure 31). This direct effect on M. 
avium viability was determined, in three independent experiments, by resazurin reduction, 
and confirmed by CFUs. The results obtained by the two techniques are highly concordant.  
 
 
 
 
 
 
 
 
Figure 31 – Effect of cecropin A-melittin-derived peptides on M. avium viability. M. avium was 
cultured in liquid medium, in the presence of 0, 6.25, 12.5, 25, 50, 100 and 200 μM of CAM, K6 and 
K7 for 7 days. The viability was measured by A) resazurin reduction, where the results were 
expressed as percentage of cell viability relative to control wells, and B) colony forming units 
(CFUs) assay. Statistical analysis was performed using the two-tailed Student’s t-test: * p<0,05; ** 
p<0,005; *** p<0,0005. The results of one representative experiment out of three are shown. 
2.1.2. Effect on M. avium growing inside macrophages and macrophage toxicity 
Recently, the hemolytic activity of CAM, K6 and K7 was determined (Fernandez-Reyes, M. 
et al. 2010), and the analogues K6 and K7 showed a significantly lower hemolytic activity 
compared to the parental hybrid peptide. However, when we tested the same peptides on 
macrophage cultures infected with M. avium, they revealed a high toxicity, assessed by 
resazurin reduction (results not shown) and by the use of VibrantTM Citotoxicity Kit Assay 
A       B [CAM] / μM        [K6] / μM         [K7] / μM 
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(figure 32). These results suggest that, although erythrocytes and macrophages are both 
mammalian cells, they are different enough, in this case probably at the plasmatic 
membrane composition, for their differential susceptibility to these peptides. 
K7 was the peptide with lower toxicity, and at 10 μM had a citotoxicity below 10% (figure 
32), but at this concentration no effect on the mycobacterial intramacrophagic growth was 
observed (results not shown). 
 
 
 
 
 
 
 
 
Figure 32 – Toxicity of cecropin A-melittin-derived peptides on infected BMMØ. The loss of 
viability of BMMØ infected with M. avium and treated with 10, 15 and 20 μM of CAM, K6 and K7 
was determined by the use of Vibrant
TM
 Citotoxicity Kit Assay, after 2 days of incubation. The 
results are presented as percentage of dead cells relative to fully lysed macrophages. 
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2.2. Lactoferin-derived peptides 
2.2.1.  Effect on M. avium viability in axenic cultures  
The direct effect of four lactoferrin-derived peptides, human and bovine lactoferricin 
(hLFcin1-11 and LFcin17-30), bovine lactoferrampin (LFampin265-284) and LFChimera, 
on M. avium was first assessed by resazurin reduction (figure 33). The first two peptides 
were tested once, and the last two, were tested twice. The results are presented as 
percentage relative to the corresponding untreated wells. Lactoferricins were the most 
active peptides, the bovine peptide being more active than the human (figure 33). 
Lactoferrampin had no effect, and LFChimera, at higher concentrations (50 and 100 μM) 
seemed to promote the growth of M. avium (figure 33). 
 
 
 
 
 
 
 
Figure 33 – Effect of lactoferrin-derived peptides on M. avium viability. M. avium was grown in 
Middlebrook 7H9 with hLFcin1-11, LFcin17-30, LFampin265-284 and LFChimera at 0, 3.13, 6.25, 
12.5, 25, 50 and 100 μM of final concentration for all the peptides. Mycobacterial viability was 
measured by resazurin reduction after 7 days of incubation. The results of one experiment 
(hLFcin1-11 and LFcin17-30) and one representative experiment out of two (LFampin265-284 and 
LFChimera) are shown and presented as percentage of viable cells relative to the corresponding 
non-treated wells (control wells). 
Since the lactoferricins appear to be the most interesting peptides, as they are active at 25 
μM and above, the quantification of mycobacteria by CFUs was performed, and again, the 
results were in agreement with the ones obtained by the resazurin reduction assay (figure 
34). Bovine lactoferricin (LFcin17-30) showed a higher inhibitory activity than human 
lactoferricin (hLFcin1-11). 
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Figure 34 – Effect of lactoferricin on M. avium viability. M. avium was incubated with A) bovine 
and B) human lactoferricin (LFcin17-30 and hLFcin1-11) at 0, 3.13, 6.25, 12.5, 25, 50 and 100 μM. 
M. avium viability was determined by CFUs, after 7 days of incubation. Statistical analysis was 
performed using the two-tailed Student’s t-test: * p<0,05; ** p<0,005; *** p<0,0005. The results of 
one experiment are shown. 
2.2.2. Effect on M. avium growing inside macrophages and macrophage toxicity 
As M. avium is an intracellular pathogen, that lives, mainly, inside macrophages, the next 
step was to test the same peptides on M. avium growing inside macrophages. 
It had been described before that this family of antimicrobial peptides could act as an 
adjuvant of conventional antibiotics potentiating their therapeutic effect (Leon-Sicairos, N. 
et al. 2006; Oo, T.Z. et al. 2010; Sanchez-Gomez, S. et al. 2011). In this work, lactoferrin-
derived peptides were combined with ethambutol, an antibiotic used to treat M. avium 
infections, to evaluate a potential synergistic effect against M. avium growing inside 
macrophages. 
Lactoferrampin at 10 μM had no effect in the growth of M. avium inside macrophages, 
even when combined with ethambutol (results not shown). 
Lactoferricins alone, human and bovine, were not effective against M. avium growing 
inside macrophages, at 20, 30 or 40 μM (figure 35 and 36). However, when each of the 
peptides was combined with ethambutol 4 μg/mL, which was also not effective alone (at 
this concentration) against M. avium growing inside macrophages, there was a synergistic 
effect (first determined for the lowest concentration of peptide – 20 μM – and then 
confirmed for this condition and tested for the other two, 30 and 40 μM) (figure 35 and 36), 
suggesting that the AMP increases the access of the antibiotic to the mycobacteria, when 
they are inside its host cell. Also in this case, as happened in the axenic assays, the 
A            B 
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bovine peptide, LFcin17-30, was the most active, inducing a significant decrease on M. 
avium growth at 20 μM, when combined with ethambutol (figure 35).  
 
 
 
 
 
 
 
Figure 35 – Effect of bovine lactoferricin on the viability of M. avium growing inside 
macrophages. BMMØ infected with M. avium were treated with 0, 20, 30 and 40 μM of LFcin17-30 
in the presence or absence of ethambutol 4 μg/mL. Intramacrophagic growth of M. avium was 
determined by CFUs after 7 days of incubation. Statistical analysis was performed using the two-
tailed Student’s t-test: * p<0,05; ** p<0,005; *** p<0,0005. The results of one experiment are shown. 
 
 
 
 
 
 
 
Figure 36 – Effect of human lactoferricin on the viability of M. avium growing inside 
macrophages. BMMØ infected with M. avium were treated with 0, 20, 30 and 40 μM of hLFcin1-11 
in the presence or absence of ethambutol 4 μg/mL. M. avium viability was measured by CFUs after 
7 days of incubation. Statistical analysis was performed using the two-tailed Student’s t-test: * 
p<0,05. The results of one experiment are shown. 
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The toxicity of lactoferricins towards macrophages was determined by resazurin reduction 
after 7 days of incubation (results are presented as percentage relative to non-treated 
infected macrophages). None of the peptides was significantly toxic for macrophages up 
to 40 μM, since the cells maintained their viability in all concentrations for both AMPs 
(figure 37). 
 
 
 
 
 
 
 
 
Figure 37 – Lactoferricin toxicity on infected BMMØ. Macrophages infected with M. avium were 
incubated with 0, 20, 30 and 40 μM of LFcin17-30 and hLFcin1-11. Macrophage viability was 
determined after 7 days of incubation, by resazurin reduction. The results are presented as 
percentage of viable cells relative to the corresponding non-treated infected wells. 
Contrarily to what happens with other AMPs, we found that 10 μM LFChimera significantly 
promoted the growth of M. avium inside macrophages (figure 38). This assay was 
repeated four times, all giving the same result. To try to understand what is the 
mechanism behind this increase in proliferation, different concentrations of LFChimera 
(2.5, 5, 10 and 15 μM) at different time points (4 and 7 days) were tested. The LFChimera 
effect was dose-dependent and already visible after 4 days of incubation (figure 38). 
 
 
 
 
 
 91 
 
0.00
0.30
0.60
0.90
1.20
1.50
0 2.5 5 10 15
lo
g
 i
n
c
re
a
s
e
 C
F
U
/m
L
[LFChimera] /μM
*
**
***
0.00
0.50
1.00
1.50
2.00
2.50
LFChimera
lo
g
 i
n
c
re
a
s
e
 C
F
U
/m
L
Control
LFChimera 10 μM
***
 
 
 
 
 
 
  
Figure 38 – Effect of LFChimera on the viability of M. avium growing inside macrophages. 
Intramacrophagic growth of M. avium was assessed by CFUs A) after 7 days of incubation when 
infected BMMØ were treated with 10 μM LFChimera, and B) after 4 days, when macrophages were 
incubated with 0, 2.5, 5, 10 and 15 μM of LFChimera. Statistical analysis was performed using the 
two-tailed Student’s t-test: * p<0,05; ** p<0,005; *** p<0,0005. The results of one representative 
experiment out of A) four and B) two are shown. 
Could this effect be an artifact due to AMP toxicity that is killing the macrophages and 
releasing the bacteria to the surrounding medium, where they grow faster than inside the 
host cell? To answer this question the toxicity of LFChimera towards macrophages in the 
same concentrations and times of incubation was measured. LFChimera was not toxic for 
infected BMMØ at any of the concentrations tested (figure 39). The results are presented 
as percentage relative to non-treated infected cells in each time-point. On day 7 post-
infection, the relative viability of macrophages actually seemed to increase with the 
increase in LFChimera concentration. In fact, in terms of absolute values what we 
observed was a decrease of viability in the untreated macrophages whereas this decrease 
was less marked in LFChimera-treated macrophages. Also, the amount of extracellular 
bacteria growing in the surrounding medium was determined being less than 20% of the 
total amount of bacteria per well (results not shown). 
To confirm that macrophages incubated with LFChimera were intact and with a higher 
number of M. avium, after 3 days of incubation infected macrophages grown in glass 
coverslips were fixed and stained with Auramine O, a green dye which stains 
mycobacteria. In figure 54, representative pictures of phase contrast and fluorescence 
microscopy of control cells, without AMP, and cells treated with 10 μM LFChimera, are 
shown. Although quantitative data were not obtained, the relative number of bacteria per 
macrophage in treated cells appears to be higher than in control cells and macrophages 
A              B 
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seem to be healthy as the morphology of the cells, as far as we can see and assess, was 
not affected (figure 40). 
  
 
 
 
 
 
Figure 39 – Toxicity of LFChimera on infected BMMØ. After 4 and 7 days of incubation of 
infected-macrophages with 0, 2.5, 5, 10 and 15 μM of LFChimera, cellular viability was determined 
by resazurin reduction. The results of one representative experiment out of two are shown and 
presented as percentage of viable cells relative to non-treated infected wells in each time-point. 
 
 
 
 
 
 
 
 
 
 
Figure 40 – Effect of LFChimera on the intramacrophagic growth of M. avium. Macrophages 
infected with M. avium for 3 days were fixed and mycobacteria were stained with Auramine O. 
Cells were photographed in a Laser Scanning Confocal Microscope Leica SP2 with final 
magnification of 630x, and representative pictures are shown. Upper panels show phase contrast 
and lower panels the corresponding fluorescence image. A) Non-treated infected macrophages. B) 
Infected macrophages treated with 10 μM LFChimera. C) Higher magnification of one macrophage 
from picture B.  
M. avium – Auramine O M. avium – Auramine O M. avium – Auramine O 
A        B           C 
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III.3 – Characterization of peptide-lipid 
interaction by X-ray diffraction 
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1. MATERIAL AND METHODS  
Lipids 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE or 16:0-18:1 PE) lipid was 
obtained from Avanti Polar Lipids (Alabaster, AL), and used without further purification. 
 
 
 
 
 
Figure 41 – Structural representation of POPE (Avanti Polar Lipids). 
 
Peptides 
To assay the peptide-lipid interaction on model membranes by X-ray diffraction, cecropin 
A-melittin derivatives (CAM, K6 and K7) and lactoferrin-derived peptides (LFcin17-30, 
LFampin265-284 and LFChimera) were used (see tables 3 and 4 on pages 55 and 56). 
 
Preparation of liposomes  
To obtain multilamellar vesicles (MLVs) of POPE, 2 methods were used: 
1. Appropriate amounts of the lipid were dissolved in a small volume of chloroform, and 
transferred to a round flask, where a film was obtained by drying the chloroform under 
a slow nitrogen flow. The film was thereafter kept under vacuum for 3h to remove all 
traces of organic solvents. The lipid film was hydrated with PBS (150 mM NaCl, pH 7.2) 
and warmed for about 1h in a thermostated bath at 35 ºC, above the main transition 
temperature (TM = ~25 ºC) and below the lamellar to hexagonal transition (TH = ~71 ºC) 
to guarantee that all lipids are in the fluid lamellar state. The resulting vesicles (MLVs) 
were frozen in liquid nitrogen and thawed in the thermostated bath, and this process 
was repeated 5 times. 
2. Appropriate amounts of the lipid were hydrated with PBS (150 mM NaCl, pH 7.2), and 
incubated for 30 min in a water bath at ~35 ºC, above the main transition temperature, 
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for the same reasons as stated above. After this, a large number of short cycles of 
alternating vortex at room temperature and heating at 35 ºC were performed. 
An aliquot of each liposome suspension was stored at -20 ºC for determination of the 
exact lipid concentration. The remaining lipid was kept at 4 ºC until use. 
 
Peptide-lipid mixture’s preparation 
Peptide solution in the same buffer used for preparing the liposomes was added to the 
liposome suspension at different peptide-to-lipid (P:L) ratios, and the mixtures were 
incubated for 30 min at 35 °C. The samples were then centrifuged at 13 000 rpm in a 
microcentrifuge at least for 15 min, and transferred thereafter into glass capillaries 
(Spezialglas Markröhrchen 1.5 mm capillaries, Glass Technik & Konstruktion – Müller & 
Müller OHG, Germany). The capillaries were sealed by flame, and stored at 4 ºC, at least 
one day before use. 
 
X-Ray diffraction  
Principles 
X-ray diffraction is a powerful tool to characterize the structure of lipid phases and 
polymorphic changes in the lipid bilayer. Lipid dispersions in water form structures with 
long-range periodic order that can be analyze by X-ray techniques, in particular by 
diffraction methods, as these periodic structures will diffract the X-rays in a particular 
pattern depending on the existent phase and the respective space group. This is 
described by Bragg’s law 
mλ = 2dsinθ 
where m is the diffraction order, λ is the wavelength of the diffracted radiation, d is the 
lattice spacing and 2θ is the scattering angle. Measurements of the intensity of the 
scattered radiation as a function of the scattering angle allows the determination of the 
lattice parameter (Hanulóva, M. 2008). 
The radiation can be diffracted at small angles, up to 3º – Small Angle X-ray Diffraction 
(SAXD) or in larger angles, up to 20º – Wide Angle X-ray Diffraction (WAXD) (Hanulóva, 
M. 2008). Therefore, by SAXD we can get information about distances in large structural 
repetitions that are in the order of 10 to several 100 Å, like the lattice parameter (e.g. 
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bilayer spacing), whereas WAXD provides information about repeating structural patterns 
at small distances (2 to 9 Å), like the hydrocarbon chain lattice, if they are not in a liquid 
disordered state. Ideally, these two distinct regions of the diffraction pattern should be 
measured simultaneously to characterize completely the structure present. 
Lamellar, hexagonal and cubic phases can be detected and characterized by X-ray 
diffraction. The first two phases are normally present in microscopic crystalline domains, 
randomly oriented throughout the sample, whereas cubic phases can grow to large 
dimensions, in some cases of the size of the sample container. With the exception of the 
last one (cubic phase), a few diffractions are enough to unequivocally describe the type of 
symmetry (e.g. lamellar or hexagonal) and to obtain the repeat distances (d or a). 
When we measure the intensity of the scattered radiation as a function of the scattering 
angle in the SAXD region (the SAXD pattern), we obtain peaks, which for a gel (Lβ) and a 
fluid lamellar phase (Lα) are equidistant (figure 1) and appear at sh = h/d (h – Miller index), 
reflecting the bilayer spacing (or lattice parameter of lamellar phase – d in figure 42). In 
WAXD a sharp peak appears for the gel lamellar phase (Lβ) and only a broad diffuse peak 
for the liquid lamellar phase, as in the gel lamellar phase the lipid chains are more 
extended and rigid, and thus have order reflections and thus this can be used to safely 
assess the presence of a gel lamellar phase (Hanulóva, M. 2008). 
 
 
 
 
 
 
 
 
Figure 42 – SAXD pattern of the fluid lamellar phase (Lα) of POPE membranes. The 
corresponding structure (adapted from: Tresset, G. 2009), is shown in the inset with the respective 
lattice parameter (d). 
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The diffraction pattern of a hexagonal phase (HII) in the SAXD region contains a series of 
peaks that appear at positions shk =(2 h
2+k2+hk   3ah) (h, k – Miller indices), where ah is 
the distance between the centers of the neighboring lipid cylinders (figure 43). In WAXD, 
similar to the fluid lamellar phase, only a broad peak appears (Hanulóva, M. 2008). 
 
 
 
 
 
 
 
Figure 43 – SAXD pattern of the inverse hexagonal phase (HII) of POPE membranes. The 
corresponding structure (adapted from: Tresset, G. 2009), is shown in the inset with the respective 
lattice parameter (ah). 
The SAXD diffraction pattern of a cubic phase shows a number of peaks at positions 
given by shkl = ( h
2+ k2+ l2 / ac) (h, k, l – Miller indices), where ac is the cubic lattice 
parameter (figure 44). The more intense peaks of the cubic phase appear at small s 
values (reciprocal spacing), reflecting the large repeating units of this phase. In the WAXD 
region a broad diffuse peak is seen (Hanulóva, M. 2008). 
 
 
 
 
 
 
Figure 44 – SAXD pattern of the cubic phase Pn3m. The corresponding structure is shown in 
the inset with the respective lattice parameter (ac) (Hanulóva, M. 2008). 
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Typically, depending on the lipid and temperature, liposomes can form lamellar or 
hexagonal phases. However the presence of an antimicrobial peptide can induce 
structural changes, either altering only the lattice parameters or leading to the formation of 
cubic phases. Understanding the type of polymorphic structure that is present in a 
peptide-lipid mixture can lead to a deeper knowledge of the mechanism of action of the 
peptide (Haney, E.F. et al. 2010). 
Method  
SAXD and WAXD experiments were performed at the synchrotron soft condensed matter 
beamline A2 in HASYLAB at Deutsches Elektronen Synchrotron (DESY), Hamburg, 
Germany, using a monochromatic radiation of λ = 0.15 nm wavelength. 
Figure 45 – Beamline A2 in Hasylab. A) A general view of the instrument is shown. B) In detail, 
the capillary holder and the two detectors for SAXD and WAXD. 
Up and down temperature scans were performed for each sample, all at a scanning rate 
of 1 ºC/min, over the temperature range 20 - 80 ºC. Diffractograms were taken with 10 s of 
exposure time at each temperature. The heating and cooling of the sample was regulated 
by a thermocouple connected to the temperature controller JUMO IMAGO 500 (JUMO 
GmbH & Co. KG, Fulda, Germany). Each SAXD diffraction pattern is presented as 
normalized diffraction intensity in arbitrary units versus the reciprocal spacing s. The 
SAXD patterns were analysed in two different ways: i) by use of the A2tool program as a 
first approach to the (qualitative) analysis of the results; and ii) quantitatively by analyzing 
each difractogram in detail, where the diffraction peaks were fitted by Lorentzians above a 
linear background by use of the Origin software, in order to derive the lattice parameters 
(d or a) that characterize the different phases present. The positions of the peaks plotted 
vs. h for a lamellar phase,  h2+hk+k2  for a hexagonal phase or  h2+k2+l2 for a cubic 
beam direction 
capillary 
holder 
SAXD 
 
WAXD 
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phase (h, k, l – Miller indices), should fall on a straight line, passing through the origin 
(0,0), and the lattice parameter d, ah or ac, for lamellar, hexagonal and cubic phase, 
respectively, is given by the inverse of the slope. WAXD measurements were used to 
verify the existence of the gel phase (Lβ) (not shown). 
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2. RESULTS 
2.1. Cecropin A-melittin-derived peptides 
2.1.1. Phase behavior of POPE membranes 
The diffraction profile of a lipid changes with temperature. In the case of pure POPE 
membranes, as the temperature increases there is a transition from gel lamellar phase (Lβ) 
to fluid lamellar phase (Lα) at 26 C, and from fluid lamellar (Lα) to hexagonal phase (HII) at 
71 C (figure 47). 
When the peptides (CAM, K6 or K7) were added to the lipid system, the transition from gel 
to fluid lamellar phase was not significantly affected, neither in terms of transition 
temperature nor in lattice value, but some changes were observed in the transition from 
fluid lamellar to hexagonal phase. This difference was already apparent in the 
temperature scan of each peptide/lipid mixture (figure 46) and later was confirmed by the 
determination of the lattice parameters (figure 47). The studied peptides have somewhat 
different effects: 
1. CAM does not alter the transition temperature to hexagonal phase. 
2. For both K6 and K7 we observed the coexistence of hexagonal phase (figure 46 – 
green arrows) together with fluid lamellar phase (figure 46 – red arrows), from 
about 10 C below the TH of pure POPE transition. This suggests that these two 
peptides destabilize the lamellar phase and have better compatibility with the 
hexagonal phase, as it appears at lower temperatures than in the absence of the 
peptide. Thus, part of the mixture moves to the hexagonal phase (peptide/POPE) 
earlier, whereas the remaining, presumably not affected by the peptide, remains in 
the lamellar phase. 
After the transition to hexagonal phase, it is possible to observe, for the three peptides, 
the superimposition of two hexagonal phases with close periodicity (figure 47). Similarly to 
the early appearance of the hexagonal phase, these two hexagonal phases are most 
probably due to the existence of distinct domains within the membrane - the peptides bind 
and destabilize only part of the membrane, this being reflected in a different lattice 
spacing of one hexagonal phase as compared to the one composed of pure lipid. For 
instance, at 80 ºC the lattice parameter of the hexagonal phase for pure POPE is 7.09 nm, 
whereas in the presence of CAM, one of the hexagonal phases has a value of 7.12 nm 
(similar to the pure lipid) and the other 6.89 nm, the same happening for the other two 
peptides (K6 – 7.11 and 6.85 nm; K7 – 7.10 and 6.88 nm). 
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Figure 46 – SAXD pattern of temperature scans of POPE membranes with cecropin A-
melittin derivatives. Graphical representation of all the diffractograms from up-and-down 
temperature scans (20-80ºC) of peptide/lipid mixtures (P:L=1:10) using the A2tool software A) 
CAM, B) K6, C) K7. The different phases present are marked by: yellow – gel lamellar phase (Lβ); 
red – fluid lamellar phase (Lα); green – hexagonal phase (HII); orange circle – cubic phases. 
 
 
 
 
 
 
Figure 47 – Phase behavior of POPE membranes with cecropin A-melittin derivatives. Lattice 
parameters (d or a) for the lamellar (Lβ and Lα) and hexagonal (HII) phases observed for the pure 
POPE and for peptide/lipid mixtures (P:L=1:10) with A) CAM, B) K6 e C) K7. Data derived from up-
scans from 20 - 80 ºC. 
With K6 and K7 it was also possible to detect the presence of two extra peaks, as marked 
in figure 46 by the pink arrows, together with the lamellar phase that do not belong either 
to this or to the hexagonal phase (figure 46 – pink arrows). With only two peaks it is 
impossible to identify unequivocally a cubic phase, but we would like to stress that these 
two peaks are always present in both samples and they are consistent with an Im3m cubic 
phase (figure 48). This could be an indication that this phase is present, already in the 
heating process. Nevertheless, further analysis with different P:L ratios (higher peptide 
content) are necessary to characterize this possible phase, leading to safer conclusions. 
 
A       B          C 
A     B          C 
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Figure 48 – Evidence for a cubic Im3m phase induced by K6 and K7 in POPE membranes. A 
plot of s = f ( h2+k2+l2 ) for the observed reflections at 23 ºC that do not fit with lamellar or 
hexagonal phase. 
In the cooling process, the temperature scan indicated, with all the peptides, the presence 
of structures of higher symmetry (several peaks observed at small s values) (figure 46 – 
orange circle), most probably a cubic phase. Further analysis was thus performed with 
these down-scans, to try to determine what was the phase present. At this moment, we 
chose to analyze in detail for all peptides the diffraction patterns at one temperature, 
namely at 50 ºC (on cooling) (tables 6-8, figure 49). The diffraction patterns are 
compatible with the coexistence of two bicontinuous cubic phases, of Im3m and Pn3m 
symmetry, and a fluid lamellar phase. It should be stressed that in some cases, due to 
very few reflections (less than 4-5) it is not possible to make a safe assignment to a 
particular lattice. For the parental hybrid peptide, CAM, the Pn3m phase is better defined 
as compared with the Im3m phase, as more peaks are observed for the first one. With the 
trimethylated peptides (K6 and K7) more peaks corresponding to an Im3m phase are 
visible, especially at higher s values. The lattice parameters determined have similar 
values between the same phases present in the three peptide/lipid mixtures (tables 6-8). 
For example the fluid lamellar phase (Lα) present in each of the three peptide/lipid 
mixtures have similar values between them (d CAM = 5.24 nm; d K6 = 5.28 nm; d K7 = 5.23 
nm). 
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Table 6 – SAXD data for POPE membranes with cecropin A-melittin derivatives, CAM, K6 and K7 
(P:L=1:10), at 50 ºC indexed to a fluid lamellar phase (Lα). The respective lattice parameter (d) is 
indicated.  
H 
Lα (s / nm
-1
) 
CAM K6 K7 
1 0.19043 0.18638 0.19076 
2 0.38225 0.38031 0.38233 
d / nm 5.24 5.28 5.23 
 
 
Table 7 – SAXD data for POPE membranes with cecropin A-melittin derivatives, CAM, K6 and K7 
(P:L=1:10), at 50 ºC indexed to a Im3m cubic phase. The respective lattice parameter (ac) is 
indicated.  
Hkl   h     l   
Im3m (s / nm-1) 
CAM K6 K7 
110 √2 0.10906 0.10547 - 
200 √4 0.15662 0.14796 0.15016 
211 √6 0.19043 - - 
220 √8 - 0.20833 - 
222 √12 - - 0.25916 
400 √16 - - 0.29894 
420 √20 - - 0.32935 
332 √22 - 0.34421 - 
ac / nm 12.85 13.59 13.44 
 
 
Table 8 – SAXD data for POPE membranes with cecropin A-melittin derivatives, CAM, K6 and K7 
(P:L=1:10) at 50 ºC indexed to a Pn3m cubic phase. The respective lattice parameter (ac) is 
indicated.  
Hkl   h     l   
Pn3m (s / nm-1) 
CAM K6 K7 
110 √2 0.08851 0.08220 0.08962 
111 √3 0.10906 0.10547 - 
200 √4 0.12834 0.12440 0.12195 
211 √6 0.15662 0.15460 0.015016 
221 √9 0.19043 0.18638 - 
310 √10 - - 0.19076 
311 √11 - 0.20833 - 
222 √12 - 0.21784 - 
321 √14 0.23547 - - 
400 √16 - 0.25490 - 
ac / nm 15.80 15.92 16.39 
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Figure 49 – Cubic phases (Im3m and Pn3m) in POPE membranes with cecropin A-melittin 
derivatives. SAXD patterns for peptide/lipid mixtures (P:L=1:10) at 50 ºC on cooling. A) CAM, B) 
K6, C) K7. Insert: A plot of s = f(  h
2
+k
2
+l
2
 ) for all observed reflections is shown.  
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2.2. Lactoferrin-derived peptides 
2.2.1. Phase behavior of POPE membranes 
In the case of all the lactoferrin-derived peptides, LFcin17-30, LFampin265-284 and 
LFChimera, no changes in parameters or transition temperatures from gel to fluid lamellar 
phase or in the transition from fluid lamellar to hexagonal phase were observed in the 
heating process (figure 50-51). The only difference was the prevalence of the first peak of 
the fluid lamellar phase after the transition to hexagonal phase when the sample was 
heated (in a small content meaning, only the first peak is visible and with a low intensity) 
in the presence of LFChimera at PL=1:18, in the heating process. However, and as for the 
first family of peptides, the presence of other structures with peaks at small s values, were 
observed when the sample was cooled down (figure 50 – orange circles). 
 
 
 
 
 
Figure 50 – SAXD pattern of temperature scans of POPE membranes with lactoferrin-derived 
peptides. Graphical representation of all diffractograms from up-and-down temperature scans (20-
80ºC) of peptide/lipid mixtures using the A2tool software A) LFcin17-30 at PL=1:8, B) LFampin265-
284 at PL=1:8 and C) LFChimera at PL=1:18. The different phases present are marked by: yellow 
arrows – gel lamellar phase (Lβ); red arrows – fluid lamellar phase (Lα); green arrows – hexagonal 
phase (HII); orange circles – cubic phases. 
 
 
 
 
 
Figure 51 – Phase behavior of POPE membranes with lactoferrin-derived peptides. Lattice 
parameters (d or a) for the lamellar (Lα and Lβ) and hexagonal (HII) phases observed for the pure 
POPE and for peptide/lipid mixtures. A) LFcin17-30 at PL=1:8, B) LFampin265-284 at PL=1:8 and 
C) LFChimera at PL=1:18. Data derived from up-scans from 20 - 80 ºC. 
 A        B         C 
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The peaks observed at small s values were also analyzed in detail (at 50 ºC on the 
cooling scan) in the same way as before (for cecropin A-melittin peptides). They also 
suggest the coexistence of two bicontinuous cubic phases (Im3m and Pn3m), together 
with a fluid lamellar phase (tables 9-11; figure 50). The lattice parameters are again 
similar between the same phases present in the three lipid/ peptide mixtures, and with the 
values obtained for the other peptide family, with the exception of LFampin265-284 that 
presents a larger cubic lattice spacing (tables 10 and 11). 
Table 9 – SAXD data for POPE membranes with lactoferrin-derived peptides: LFcin17-30 (PL=1:8), 
LFampin265-284 (PL=1:8) and LFChimera (PL=1:18) at 50 ºC indexed to a fluid lamellar phase (Lα). 
The respective lattice parameter (d) is indicated. 
H 
 Lα (s / nm
-1
) 
 LFcin LFampin LFChimera 
1  0.19105 0.19182 0.19147 
2  0.38362 0.38464 0.38372 
d / nm  5.22 5.20 5.21 
Table 10 – SAXD data for POPE membranes with lactoferrin-derived peptides: LFcin17-30 
(PL=1:8), LFampin265-284 (PL=1:8) and LFChimera (PL=1:18) at 50 ºC indexed to a Im3m cubic 
phase. The respective lattice parameter (ac) is indicated. 
Hkl   h     l   
Im3m (s / nm-1) 
LFcin LFampin LFChimera 
110 √2 0.10659 0.099021 0.10642 
200 √4 0.15303 0.14008 0.14725 
211 √6 - 0.17561 - 
310 √10 - - 0.2368 
400 √16 - - 0.29612 
330 √18 0.31718 - 0.31485 
420 √20 - 0.32043 - 
ac / nm 13.32 14.00 13.46 
Table 11 – SAXD data for POPE membranes with lactoferrin-derived peptides: LFcin17-30 
(PL=1:8), LFampin265-284 (PL=1:8) and LFChimera (PL=1:18) at 50 ºC indexed to a Pn3m cubic 
phase. The respective lattice parameter (ac) is indicated. 
Hkl   h     l   
Pn3m (s / nm-1) 
LFcin LFampin LFChimera 
110 √2 0.087868 0.079632 0.087068 
111 √3 0.10659 0.094663 0.10642 
200 √4 0.12030 0.11129 0.12390 
211 √6 0.15303 0.13350 0.015259 
310 √10 - 0.17561 0.19147 
222 √12 - 0.19182 - 
ac / nm 16.23 18.08 16.29 
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Figure 52 – Cubic phases (Im3m and Pn3m) in POPE membranes with lactoferrin-derived 
peptides. SAXD patterns for peptide/lipid mixtures at 50 ºC on cooling. A) LFcin17-30 at PL=1:8, B) 
LFampin265-284 at PL=1:8 and C) LFChimera at PL=1:18. Insert: A plot of s = f(  h
2
+k
2
+l
2
 ) for all 
observed reflections is shown. 
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DISCUSSION & CONCLUSIONS 
In this work we used microbiological and biophysical techniques to study the effects of 
cecropin A-melittin derived and lactoferrin-derived peptides, on different pathogens and on 
model membranes. 
The antimicrobial activity of cecropin A-melittin derivatives was assessed against 
Mycobacterium avium in axenic cultures (bacteria growing in liquid medium) and in 
cultures of macrophages, the cell inside which mycobacteria usually grow. CAM, K6 and 
K7 directly inhibit M. avium growth above 50 μM but even at 200 μM the growth inhibition 
did not reach 50%. This lack of significant effect suggests that these peptides are not able 
to crossover the highly impermeable and complex mycobacterial cell wall. In addition, 
these peptides are toxic towards macrophages at much lower concentrations, the 
cytotoxicity of CAM and K6 at 20 μM overpassing 50%. For concentrations at which the 
toxicity does not reach 10%, no effect on the viability of M. avium growing inside 
macrophages was seen. 
All these results discourage the use of these particular peptides as therapeutic agents 
against mycobacterial infections, as their activity was very low and they cannot be used 
on macrophages, the host cell of these bacteria. Nevertheless the results are interesting 
in some points of view. For instance, recent studies showed that the hemolytic activity of 
the trimethylated peptides K6 and K7 was very low (Fernandez-Reyes, M. et al. 2010), 
which was seen as a promising characteristic in terms of therapeutic utility. However, our 
results showing that the peptides were toxic towards macrophages, indicate that although 
erythrocytes and macrophages are both mammalian cells, there must be crucial 
differences in their cellular membranes. This suggests that the use of erythrocytes only as 
target cells for determination of AMP toxicity may be misleading. The differential effects of 
cecropin A-mellitin peptides on different cell types could be more clarified with biophysical 
studies using model membranes mimicking these different cells. Until now the most 
common model membrane of choice for mammalian cells is solely composed by 
phospatidylcholine (PC) the main lipid of the cellular membrane of erythrocytes. The lipid 
composition of the cytoplasmic membrane of macrophages must be very different from 
the membrane of erythrocytes, containing other phospholipids and possibly changing the 
relative amounts, and this could explain the differences in behavior that we encountered. 
However the knowledge about the lipid composition of the macrophage cytoplasmic 
membrane is poor and so no model membranes more specific for these cells are known 
up to now. The use of lipidomics, for instance, could be useful to try to uncover this 
composition, and be subsequently used to make model membranes, leading to a deeper 
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knowledge on how these peptides, and others, interact with these types of cells, and in 
that way refine the applicability of the biophysical techniques as screening methods for the 
antimicrobial activity of the AMPs. We hope to use this in the future. 
We have also investigated the effects of several lactoferrin-derived peptides on two 
intramacrophagic pathogens, Leishmania and Mycobacterium avium. 
In this study, we found that Lactoferricin (LFcin17-30), lactoferrampin (LFampin265-284) 
and LFChimera were active against L. donovani promastigotes, and LFChimera is of 
special interest due to its high activity both against L. donovani promastigotes and L. 
pifanoi amastigotes. Our results indicate that the leishmanicidal mechanism of these 
AMPs consists on targeting the plasma membrane, leading to its permeabilization that 
culminates into bioenergetic collapse of the parasites due to loss of the ionic gradient and 
leakage of ATP, and also leakage of the cytoplasmic content, ending in parasitic death. 
The mechanism of action of LFcin17-30 was also very interesting and peculiar, as it 
appears to induce cellular aggregation. The fact that this peptide was able to reach 
intracellular amastigotes when they were inside its host cell strongly suggests that it will 
also be able to exert its leishmanicidal effect inside macrophages. However, the effect of 
this peptide on the parasitic load inside macrophages was not determined. Future 
experiments will be performed to address this question. 
The activity of LFChimera against L. donovani promastigotes was much higher than the 
sum of its separated components, revealing that having the two peptides, LFcin17-30 and 
LFampin265-284, bond to each other is important for the antimicrobial activity. To try to 
understand what are the special features in LFChimera that make this peptide so active, a 
set of surrogates that varied some of the characteristics of this peptide, such as charge, 
order of the constituent peptides (LFcin17-30 and LFampin265-284), and the bond 
between them, were also tested. The activity against Leishmania parasites of all the 
peptides was equal or higher than the parental peptide. Two of these peptides, Di-LFcin 
and especially LFampin-LFcin, were found to have higher activity than LFChimera, 
against both forms of the parasite, promastigotes and amastigotes. This is in contrast with 
the LFChimera, which was less active in amastigotes as compared to promastigotes. 
These results suggest that the charge (higher in Di-LFcin in comparison to LFChimera) is 
important for the activity of AMPs and that the bond between the peptides appears to play 
an important role too, as in the most potent surrogate (LFampin-LFcin) instead of having 
the peptides linked by an additional lysine in a special linkage through the side chain (like 
in LFChimera), they are linked trough a normal peptide bond. So, the attempt to reach 
structure-activity relationships is not yet fully accomplished, as the experiments so far 
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were limited to the small number of surrogates available, and so, further studies will be 
done with different surrogates to obtain deeper information about structure-activity 
relationships. Nevertheless we should stress that at least two very promising peptides 
were found, with high antimicrobial activity that makes them good candidates to fight 
leishmaniasis. Further studies should be done in order to understand what are the 
antimicrobial mechanisms of these peptides. Also of importance, their toxicity towards 
mammalian cells, such as macrophages and erythrocytes, should be carefully evaluated. 
Lactoferrin-derived peptides had variable impact on the growth of M. avium. 
Lactoferrampin had no effect against M. avium either in axenic cultures or growing inside 
macrophages. Lactoferricins (human, hLFcin1-11, and bovine, LFcin17-30, peptide) 
significantly inhibited the growth of M. avium axenically at and above 25 μM. Although 
they did not inhibit the growth of M. avium inside macrophages up to 40 μM, they showed 
a synergistic effect with ethambutol in this model. These results suggest that the peptide 
is increasing the access of the antibiotic to the mycobacteria that are growing inside the 
phagosome of the macrophage. This synergistic effect of lactoferricin with conventional 
antibiotics was already shown for several other pathogens (Gifford, J.L. et al. 2005; 
Jenssen, H. & Hancock, R.E. 2009; Leon-Sicairos, N. et al. 2006; Oo, T.Z. et al. 2010; 
Sanchez-Gomez, S. et al. 2011). It is thought that this peptide disturbs the membrane, in 
this case the cytoplasmic membrane of the macrophage and/ or the phagosome 
membrane, probably by forming transient pores increasing the permeability of the 
membrane not only to the peptide itself but also to compounds that are close to these 
pores, such as the antibiotic. The combined efficacy could also be due to a more localized 
effect on the mycobacteria cell wall. The peptide could induce dissipation of the proton-
motive force resulting in decreased activity of ATP-dependent multidrug efflux pumps, 
allowing in that way the entrance of the antibiotic (Gifford, J.L. et al. 2005). Nevertheless, 
whatever the mechanisms are, the combination of lactoferricin with antibiotics like 
ethambutol, for the treatment of mycobacterial infections, as for others, has many 
advantages such as the decrease in the antibiotic dosages and in the duration of the 
treatment, and more important the decreased ability of the bacteria to acquire resistance 
to both AMPs and antibiotics. 
LFChimera, contrary to the effect observed on Leishmania and on other pathogens 
(Bolscher, J.G.M. et al. 2009; Flores-Villasenor, H. et al. 2010; Leon-Sicairos, N. et al. 
2009; Lopez-Soto, F. et al. 2010), did not inhibit the growth of M. avium. In fact the 
number of M. avium growing inside macrophages increased almost two-fold in the 
presence of LFChimera at 10 μM. This result was found to be dose-dependent and 
statistically significant as early as 4 days after infection, with no apparent impact on 
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macrophage viability. Indeed the macrophage viability after 7 days of infection and 
incubation with LFChimera was maintained at somewhat higher levels than in untreated 
macrophages. These unexpected results raise the question of the mechanisms underlying 
the increased growth of M. avium. We can try to propose some explanations. This peptide 
could be: i) inhibiting a mechanism that normally contributes for bacterial growth restriction 
(like production of reactive oxygen and/ or nitrogen species); ii) facilitating the access of 
the bacteria to some critical nutrient or growth factor; iii) interfering with lipid metabolism 
and iron availability; iv) interfering with the characteristics of the membranes of 
mycobacteria-containing phagosomes, since AMPs act on membranes, and so many 
more. Understanding the processes driving this effect could help to clarify the 
mechanisms by which macrophages actually control the intracellular growth of 
mycobacteria, leading to the discovery of possible new targets for antimicrobial agents. 
Also somewhat conflicting are other results revealing that LFChimera was toxic towards 
peritoneal macrophages infected with L. pifanoi amastigotes. This difference in toxicity 
between mycobacteria-infected BMMØ and leishmania-infected-peritoneal macrophages 
could result from: 
- the peptide-to-cell ratio. Although the concentrations of peptide was the same in both 
assays the amount of peritoneal cells was 5 times less than the amount of bone 
marrow derived macrophages (BMMØ) used in the mycobacterial infections, so the 
number of peptide molecules per cell is much higher in the case of peritoneal 
macrophages. 
- the type of medium. The peritoneal macrophages were kept in HBSS buffer 
supplemented with D-glucose 10 mM, whereas BMMØ were cultured in a complete 
medium with 10% of fetal bovine serum that can potentially decrease the toxicity of the 
peptide. 
- peritoneal macrophages and BMMØ are primary macrophages but the first ones are 
more differentiated, with less capacity to maintain viability in culture, potentially being 
more susceptible to the activity of the peptides. 
So the comparison of results obtained with different techniques and different cells should 
be done very carefully and every variable should be considered before taking any 
definitive conclusion. 
In an attempt to shed some light on the mechanism of action of these families of peptides, 
the interaction between AMPs and simple model membranes was characterized in 
this work by a biophysical technique, SAXD. 
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The choice of the lipid composition of the model membranes is important when we want to 
use biophysical results to help interpret the biological action. As such, we have used 
mainly model membranes of phosphatidylethanolamine (PE), as it is the most abundant 
phospholipid of the bacterial membranes. Studies were also performed with lipid mixtures 
composed of PE and phosphatidylglicerol (PG), as PG is also one of the major 
phospholipids in the bacteria cell membrane, being one of the main responsible for its 
characteristic negative charge. Nevertheless, these results are still being analyzed. 
Studying the phase behavior of the model membranes in the absence and presence of 
AMPs can provide information about their mechanism of action. By SAXD we can retrieve 
this structural information by studying the lamellar/non-lamellar phase transitions and the 
changes induced by the presence of the peptide. In the last years growing evidence is 
showing that AMPs are able to induce or favor the formation of non-lamellar phases, 
namelly three dimensional cubic phases, as part of their mechanism of action (Bastos, M. 
et al. 2011; Haney, E.F. et al. 2010; Zweytick, D. et al. 2008). The formation of such cubic 
phases, could indicate that the peptides act by promoting an extensive curvature of the 
bilayer, leading eventually to disruption of the membrane and leakage of the cell content 
and thereby cell death. Also the existence of cubic phase could indicate that the peptide is 
inducing cubic domains in the membranes compatible with the formation of toroidal pores, 
a proposed mechanism for the action of AMPs. 
All the peptides analyzed induce the formation of bicontinuous cubic phases in POPE 
liposomes (Pn3m and Im3m) on the cooling process. However each family of peptides 
affects differently the transition temperatures from lamellar (Lα) to hexagonal phase (HII), 
in the heating process. In the cecropin A-melittin family all peptides induce changes in the 
hexagonal phase, either by the existence of two hexagonal phases superimposed or, in 
the case of the trimethylated peptides (K6 and K7), by the early appearance of the 
hexagonal phase (10ºC bellow the temperature observed for the pure lipid system), 
whereas in the case of lactoferrin-derived peptides no changes were observed in this 
transition (Lα → HII). 
The main conclusion at this point is thus that the interaction strongly depends on the 
peptides, and even in the same peptide family quite different patterns of interaction can be 
observed (e.g. trimethylated peptides, K6 and K7). It should be noted that the behavior 
also depends on lipid composition – in a recent study (Bastos, M. et al. 2011) we found 
that lactoferrampin (LFampin265-284) induces the formation of a micellar cubic phase 
(Pm3n) in model membranes of PC/PG, whereas in the case of PE membranes the same 
peptide induces the formation of bicontinuous cubic phases. So the interaction between 
AMPs and lipid membranes is not as unspecific as it was thought some years ago, the 
 116 
 
details of the interaction go beyond the plain existence of charge at the surface of the 
bilayer. Although this is work still in progress, we can clearly say at this point that the use 
of biophysical techniques can help to define the importance of a lipid composition in the 
overall mechanism of action of antimicrobial peptides and predict their antimicrobial 
activity. 
To follow this work, further experiments with lactoferrin-derived peptides are warranted. 
The potential of LFcin17-30, as well as lactoferricin variants (to be designed de novo) for 
synergism with other antibiotics, such as rifampicin and clarithromycin, will be assessed 
against M. avium growing inside macrophages. 
The mechanism by which LFChimera promotes the growth of M. avium inside 
macrophages will be assessed by: 
- infecting macrophages with different intracellular pathogens in order to determine if the 
effect observed for M. avium is exclusive for this bacteria; 
- activating macrophages with LPS and IFN-γ, for example, and evaluate the effect of 
LFChimera on the levels of macrophage antimicrobial molecules (e.g. NO); 
- infecting phox- and iNOS-deficient macrophages with M. avium and treating with 
LFChimera to ask whether the growth-promoting effect of the peptide depends in any 
way on oxygen and nitrogen reactive species; 
- characterizing LFChimera’s distribution inside non-infected and infected macrophages 
and the ability of the peptide to reach M. avium containing phagosomes by confocal 
microscopy using fluorescence-labeled LFChimera; 
- determining the impact of LFChimera on the degree of maturation of M. avium-
containing phagosomes by confocal microscopy, using appropriate fluorescent probes 
and molecular markers; 
- assessing the integrity of phagosomal and other macrophage membranes when 
treated with LFChimera by electron microscopy; 
- determining the effect of LFChimera surrogates on M. avium growing inside 
macrophages, trying to determine which features of LFChimera are important for the 
mechanism of promoting the intracellular growth of M. avium. 
The interaction of these peptides with simple model membranes prepared with different 
combinations of PC, PG, PE, LPS, phosphatidylserine and cardiolipin, will be assess by 
Differential Scanning Calorimetry (DSC) and by X-ray diffraction (SAXD and WAXD). 
More complex preparations of model membranes with extracts of bacteria and extracts of 
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macrophage membranes will also be used, trying to show distinctive patterns 
characteristic of each peptide/ cell interaction. 
As a final note we would like to stress that although no immediate or straightforward 
correlation is apparent between the microbiological and biophysical results, it has been 
the aim of the groups of Salomé Gomes and Margarida Bastos to perform these studies in 
parallel, as we have been getting input from the results in one area to lead to changes in 
procedure or way of “reasoning” in the other. The biophysical insight can help 
understanding some features of microbiological action, and conversely the later results 
direct the way that future biophysical experiments are designed. 
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